Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptansc1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:46:27 ON 11 APR 2008

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 15:47:31 ON 11 APR 2008

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 APR 2008 HIGHEST RN 1013659-13-6
DICTIONARY FILE UPDATES: 10 APR 2008 HIGHEST RN 1013659-13-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10566012A.str



chain nodes :
1 2 3 4 5 6 7
chain bonds :
1-2 2-3 3-4 4-5 5-6 5-7
exact/norm bonds :
1-2 2-3 3-4 5-6 5-7
exact bonds :
4-5

Match level :
1:Atom 2:CLASS 3:Atom 4:CLASS 5:CLASS 6:CLASS 7:CLASS
Generic attributes :
1:
Saturation : Unsaturated

3:
Saturation : Unsaturated

Element Count :
Node 1: Limited
S,S1

Node 3: Unlimited
N,N1-3
O,O0-3
S,S0-3

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s sss sam l1
SAMPLE SEARCH INITIATED 15:47:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 457733 TO ITERATE

0.4% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 9116071 TO 9193249
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10566012B.str



chain nodes :
1 2 3 4 5 6
chain bonds :
1-2 2-3 3-4 4-5 4-6
exact/norm bonds :
1-2 2-3 4-5 4-6
exact bonds :
3-4

Match level :
1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 6:CLASS
Generic attributes :
1:
Saturation : Unsaturated
2:
Saturation : Unsaturated

Element Count :
Node 1: Limited
S,S1

Node 2: Limited
N,N1-3
O,O0-3
S,S0-3

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s sss sam l3
SAMPLE SEARCH INITIATED 15:49:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 457733 TO ITERATE

0.4% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

```
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      9116071 TO  9193249
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L3

=> logoff y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     1.84       2.26

STN INTERNATIONAL LOGOFF AT 15:50:03 ON 11 APR 2008


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptansc1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  JAN 02  STN pricing information for 2008 now available
 NEWS  3  JAN 16  CAS patent coverage enhanced to include exemplified
                  prophetic substances
 NEWS  4  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                  custom IPC display formats
 NEWS  5  JAN 28  MARPAT searching enhanced
 NEWS  6  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS  7  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS  8  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS  9  FEB 08  STN Express, Version 8.3, now available
 NEWS 10  FEB 20  PCI now available as a replacement to DPCI
 NEWS 11  FEB 25  IFIREF reloaded with enhancements
 NEWS 12  FEB 25  IMSPRODUCT reloaded with enhancements
 NEWS 13  FEB 29  WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                  U.S. National Patent Classification
 NEWS 14  MAR 31  IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                  IPC display formats
 NEWS 15  MAR 31  CAS REGISTRY enhanced with additional experimental
                  spectra
 NEWS 16  MAR 31  CA/CAplus and CASREACT patent number format for U.S.
                  applications updated
 NEWS 17  MAR 31  LPCI now available as a replacement to LDPCI
 NEWS 18  MAR 31  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 19  APR 04  STN AnaVist, Version 1, to be discontinued
```

```
 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:13:52 ON 11 APR 2008

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:14:00 ON 11 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 APR 2008  HIGHEST RN 1013659-13-6
DICTIONARY FILE UPDATES:  10 APR 2008  HIGHEST RN 1013659-13-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s sc4/es
L1      909248 SC4/ES

=>
Uploading C:\Program Files\Stnexp\Queries\10566012C.str
```



chain nodes :
1 2 3 4 5 6
chain bonds :
1-2 2-3 3-4 4-5 4-6
exact/norm bonds :
1-2 2-3 4-5 4-6
exact bonds :
3-4

Match level :
1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 6:CLASS
Generic attributes :
1:
Saturation : Unsaturated
2:
Saturation : Unsaturated

Element Count :
Node 1: Limited
S,S1

Node 2: Limited
N,N1-3
O,O0-3
S,S0-3

L2 STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s sss sam subset=L1 l2
SAMPLE SUBSET SEARCH INITIATED 16:18:15 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -    14414 TO ITERATE

 13.9% PROCESSED     2000 ITERATIONS                              16 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):          ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):      281088 TO   295472
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):           1662 TO     2950

L3           16 SEA SUB=L1 SSS SAM L2

=> d scan

L3   16 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   INDEX NAME NOT YET ASSIGNED
MF   C51 H69 N5 O6 S4 Si . C51 H68 N8 O4 S4 Si

     CM   1

Absolute stereochemistry.
```

PAGE 1-A



PAGE 1-B



```
     CM   2

Absolute stereochemistry.
```

PAGE 1-A



PAGE 1-B



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C19 H17 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,3,4-Oxadiazole-3(2H)-propanoic acid, 2-oxo-5-(2-thienyl)-, (4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl ester
MF C17 H13 N5 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,3,4-Oxadiazole-2-propanoic acid, 5-(3-thienyl)-
MF C9 H8 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Thiazoleacetic acid, 2-(2-thienyl)-, 2,3,6-trimethylphenyl ester
MF C18 H17 N O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Pyrrole-2-propanoic acid, 1-[[2-[(4-chlorophenyl)amino]-2-oxoacetyl]amino]-5-(2-thienyl)-
MF C19 H16 Cl N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)-, 1-cyanoethyl ester
MF C18 H14 N2 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,3,4-Oxadiazole-3(2H)-propanoic acid, 2-oxo-5-(2-thienyl)-, [3-[4-(1-methylethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl ester
MF C21 H20 N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4H-1,2,4-Triazole-4-acetic acid, 3-[[(5-acetyl-2-methoxyphenyl)methyl]thio]-5-(2-thienyl)-
MF C18 H17 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzothiazolium, 3-(carboxymethyl)-2-[[3-(carboxymethyl)-5-(2-thienyl)-2(3H)-benzothiazolylidene]methyl]-5-(2-thienyl)-, inner salt
MF C27 H18 N2 O4 S4



L3 16 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Pyrrole-2-propanoic acid, 1-[[2-[(4-fluorophenyl)amino]-2-oxoacetyl]amino]-5-(2-thienyl)-
MF C19 H16 F N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Program Files\Stnexp\Queries\10566012D.str





chain nodes :
1 2 3 4 5 6 12
chain bonds :
1-2 2-3 3-4 4-5 4-6 6-12
exact/norm bonds :
1-2 2-3 4-5 4-6 6-12
exact bonds :
3-4

G1:H,Ak

Match level :
1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 6:CLASS 12:CLASS
Generic attributes :
1:
Saturation : Unsaturated
2:
Saturation : Unsaturated

Element Count :
Node 1: Limited
S,S1

Node 2: Limited
    N,N1-3
    O,O0-3
    S,S0-3

L4   STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4   STR



Structure attributes must be viewed using STN Express query preparation.

=> s sss sam subset=L1 l4
SAMPLE SUBSET SEARCH INITIATED 16:23:58 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -   14414 TO ITERATE

 13.9% PROCESSED   2000 ITERATIONS   13 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):   ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):   281088 TO   295472
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):   1293 TO   2453

L5   13 SEA SUB=L1 SSS SAM L4

=> d scan

L5   13 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   1H-1,2,4-Triazole-1-acetic acid, 4,5-dihydro-4-(2-methylpropyl)-5-oxo-3-(3-
     thienyl)-, ethyl ester
MF   C14 H19 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):13

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Pyrrole-2-propanoic acid, 1-[[2-[(4-chlorophenyl)amino]-2-oxoacetyl]amino]-5-(2-thienyl)-
MF C19 H16 Cl N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4H-1,2,4-Triazole-4-acetic acid, 3-[[(5-acetyl-2-methoxyphenyl)methyl]thio]-5-(2-thienyl)-
MF C18 H17 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H17 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,3,4-Oxadiazole-2-propanoic acid, 5-(3-thienyl)-
MF C9 H8 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)-, 1-cyanoethyl ester
MF C18 H14 N2 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Imidazolidinepropanoic acid, 2,5-dioxo-1-(3-thienyl)-, (4S)-
MF C10 H10 N2 O4 S

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C19 H17 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzothiazolium, 3-(carboxymethyl)-2-[[3-(carboxymethyl)-5-(2-thienyl)-2(3H)-benzothiazolylidene]methyl]-5-(2-thienyl)-, inner salt
MF C27 H18 N2 O4 S4



L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,3,4-Oxadiazole-3(2H)-propanoic acid, 2-oxo-5-(2-thienyl)-, [3-[4-(1-methylethyl)phenyl]-1,2,4-oxadiazol-5-yl]methyl ester
MF C21 H20 N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Pyrazolo[3,4-b]pyridine-1-acetic acid, 3-cyclopropyl-4-(2-thienyl)-
MF C15 H13 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,3,4-Oxadiazole-3(2H)-propanoic acid, 2-oxo-5-(2-thienyl)-, (4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl ester
MF C17 H13 N5 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Pyrrole-2-propanoic acid, 1-[[2-[(4-fluorophenyl)amino]-2-oxoacetyl]amino]-5-(2-thienyl)-
MF C19 H16 F N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 16:13:52 ON 11 APR 2008)

FILE 'REGISTRY' ENTERED AT 16:14:00 ON 11 APR 2008
L1 909248 S SC4/ES
L2 STRUCTURE UPLOADED
L3 16 S SSS SAM L2 SUB=L1
L4 STRUCTURE UPLOADED
L5 13 S SSS SAM L4 SUB=L1

=> s sc4/es and 2 5/sz
909248 SC4/ES
10250073 2/SZ.CNT
8610663 5/SZ
1322855 2 5/SZ
(2/SZ.CNT (T) 5/SZ)

L6 248788 SC4/ES AND 2 5/SZ

=> s l4 subset=l6 sam
SAMPLE SUBSET SEARCH INITIATED 16:28:22 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 3293 TO ITERATE

60.7% PROCESSED 2000 ITERATIONS 17 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 62419 TO 69301
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 242 TO 876

L7 17 SEA SUB=L6 SSS SAM L4

=> d scan

L7 17 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3(2H)-Thiazoleacetic acid, 2-oxo-4-(2-thienyl)-
MF C9 H7 N O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L7 17 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Pyrrole-2-propanoic acid, 1-[[2-[(4-fluorophenyl)amino]-2-oxoacetyl]amino]-5-(2-thienyl)-
MF C19 H16 F N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 17 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4H-1,2,4-Triazole-4-acetic acid, 3-[[(5-acetyl-2-methoxyphenyl)methyl]thio]-5-(2-thienyl)-
MF C18 H17 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 17 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)-, 1-cyanoethyl ester
MF C18 H14 N2 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 17 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3(2H)-Thiazolepropanoic acid, 2-oxo-4-(2-thienyl)-
MF C10 H9 N O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 17 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Pyrrole-2-propanoic acid, 1-[[2-[(4-chlorophenyl)amino]-2-oxoacetyl]amino]-5-(2-thienyl)-
MF C19 H16 Cl N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.41	27.62

FILE 'STNGUIDE' ENTERED AT 16:29:17 ON 11 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 4, 2008 (20080404/UP).

=> logoff h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.12	27.74

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:30:23 ON 11 APR 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

```
LOGINID:ssptansc1625

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 16:35:42 ON 11 APR 2008
FILE 'STNGUIDE' ENTERED AT 16:35:42 ON 11 APR 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.12      27.74

=> d his

     (FILE 'HOME' ENTERED AT 16:13:52 ON 11 APR 2008)

     FILE 'REGISTRY' ENTERED AT 16:14:00 ON 11 APR 2008
L1       909248 S SC4/ES
L2              STRUCTURE UPLOADED
L3           16 S SSS SAM L2 SUB=L1
L4              STRUCTURE UPLOADED
L5           13 S SSS SAM L4 SUB=L1
L6       248788 S SC4/ES AND 2 5/SZ
L7           17 S L4 SAM SUB=L6

     FILE 'STNGUIDE' ENTERED AT 16:29:17 ON 11 APR 2008

=> s l4 subset=l6 sam
'SUBSET' IS NOT A VALID SEARCH SCOPE
For an explanation enter "HELP SEARCH SCOPES"

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.24      27.86

FILE 'REGISTRY' ENTERED AT 16:36:56 ON 11 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 APR 2008  HIGHEST RN 1013659-13-6
DICTIONARY FILE UPDATES:  10 APR 2008  HIGHEST RN 1013659-13-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s l4 sam sub=l6
SAMPLE SUBSET SEARCH INITIATED 16:37:22 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -     3293 TO ITERATE

 60.7% PROCESSED     2000 ITERATIONS                              17 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):       62419 TO    69301
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):            242 TO      876

L8           17 SEA SUB=L6 SSS SAM L4

=> d scan

L8   17 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   1,3,4-Oxadiazole-2-propanoic acid, 5-(3-thienyl)-
MF   C9 H8 N2 O3 S
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l4 full sub=l6
FULL SUBSET SEARCH INITIATED 16:37:46 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -    65888 TO ITERATE

100.0% PROCESSED    65888 ITERATIONS                          1057 ANSWERS
SEARCH TIME: 00.00.02

L9         1057 SEA SUB=L6 SSS FUL L4

=> s sc4/es and nc4/es
        909248 SC4/ES
       1863309 NC4/ES
L10      42134 SC4/ES AND NC4/ES

=> s l9 not l10
L11        851 L9 NOT L10

=> d scan

L11  851 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)-, 2-[(3,4-
     dimethoxyphenyl)amino]-2-oxoethyl ester
MF   C25 H22 N2 O5 S2
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L11 851 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)-, 2-[(2-methyl-5-nitrophenyl)amino]-2-oxoethyl ester
MF C24 H19 N3 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 851 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4H-1,2,4-Triazole-4-acetic acid, 3-[[(5-acetyl-2-methoxyphenyl)methyl]thio]-5-(2-thienyl)-
MF C18 H17 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 851 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Pyrazole-1-acetic acid, 5-[5-[3-(methylsulfonyl)phenyl]-2-thienyl]-3-(trifluoromethyl)-
MF C17 H13 F3 N2 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 851 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5-Thiazoleacetic acid, 2-amino-4-(4-chloro-2-thienyl)-, methyl ester
MF C10 H9 Cl N2 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 851 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-
MF C16 H12 Cl N O4 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

     (FILE 'HOME' ENTERED AT 16:13:52 ON 11 APR 2008)

     FILE 'REGISTRY' ENTERED AT 16:14:00 ON 11 APR 2008
L1   909248 S SC4/ES
L2   STRUCTURE UPLOADED
L3   16 S SSS SAM L2 SUB=L1
L4   STRUCTURE UPLOADED
L5   13 S SSS SAM L4 SUB=L1
L6   248788 S SC4/ES AND 2 5/SZ
L7   17 S L4 SAM SUB=L6

     FILE 'STNGUIDE' ENTERED AT 16:29:17 ON 11 APR 2008

     FILE 'REGISTRY' ENTERED AT 16:36:56 ON 11 APR 2008
L8   17 S L4 SAM SUB=L6
L9   1057 S L4 FULL SUB=L6
L10   42134 S SC4/ES AND NC4/ES
L11   851 S L9 NOT L10

=> save temp l11 jung10566012/a
ANSWER SET L11 HAS BEEN SAVED AS 'JUNG10566012/A'

=> fil caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   190.96   218.82

FILE 'CAPLUS' ENTERED AT 16:40:27 ON 11 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 10 Apr 2008 (20080410/ED)


```
=> s l11
L12         92 L11

=> s l12 and (ay<2004 or py<2004 or pry<2004)
       4766873 AY<2004
      23980307 PY<2004
       4245576 PRY<2004
L13         75 L12 AND (AY<2004 OR PY<2004 OR PRY<2004)

=> s l13 and glucagon
         26594 GLUCAGON
           166 GLUCAGONS
         26619 GLUCAGON
                 (GLUCAGON OR GLUCAGONS)
L14          1 L13 AND GLUCAGON

=> s l13 and glp
          4028 GLP
           102 GLPS
          4074 GLP
                 (GLP OR GLPS)
L15          1 L13 AND GLP

=> s l15 not l14
L16          0 L15 NOT L14

=> s l13 and (oxazol?)
         44096 OXAZOL?
L17         21 L13 AND (OXAZOL?)

=> s l13 and (thiazol?)
         58984 THIAZOL?
L18         29 L13 AND (THIAZOL?)

=> s l13 and (triazo?)
         49296 TRIAZO?
L19          8 L13 AND (TRIAZO?)

=> s l13 and (oxadiazol?)
         15102 OXADIAZOL?
L20          5 L13 AND (OXADIAZOL?)

=> s l13 and (thiadiazol?)
         17203 THIADIAZOL?
```

```
L21           4 L13 AND (THIADIAZOL?)

=> s l17 or l18 or l19 or l20 or l21
L22          48 L17 OR L18 OR L19 OR L20 OR L21

=> dup remove l22
PROCESSING COMPLETED FOR L22
L23          48 DUP REMOVE L22 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr l23 1-48

L23  ANSWER 1 OF 48  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:182658  CAPLUS  Full-text
DOCUMENT NUMBER:          142:280193
TITLE:                    Preparation of heterocyclylalkanoic acid derivatives
                          for oral delivery of a glucagon like peptide (glp)-1
                          compound or an melanocortin 4 receptor (mc4) agonist
                          peptide
INVENTOR(S):              Jungheim, Louis Nickolaus; McGill, John McNeill, III;
                          Thrasher, Kenneth Jeff; Herr, Robert Jason;
                          Muralikrishna, Valluri
PATENT ASSIGNEE(S):       Eli Lilly and Company, USA
SOURCE:                   PCT Int. Appl., 23 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2005019212        A1    20050303    WO 2004-US24387        20040818 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004267044        A1    20050303    AU 2004-267044         20040818 <--
     CA 2530983           A1    20050303    CA 2004-2530983        20040818 <--
     EP 1658285           A1    20060524    EP 2004-779447         20040818 <--
     EP 1658285           B1    20070502
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     CN 1832944           A     20060913    CN 2004-80022791       20040818 <--
     BR 2004013676        A     20061024    BR 2004-13676          20040818 <--
     AT 350369            T     20070115    AT 2004-779446         20040818 <--
     JP 2007502817        T     20070215    JP 2006-523866         20040818 <--
     AT 361294            T     20070515    AT 2004-779447         20040818 <--
     ES 2278346           T3    20070801    ES 2004-779446         20040818 <--
     ES 2286679           T3    20071201    ES 2004-779447         20040818 <--
     US 20070293423       A1    20071220    US 2006-566012         20060125 <--
     IN 2006KN00255       A     20070323    IN 2006-KN255          20060201 <--
     MX 2006PA01916       A     20060517    MX 2006-PA1916         20060217 <--
PRIORITY APPLN. INFO.:                       US 2003-496537P     P  20030820 <--
```

OTHER SOURCE(S): CASREACT 142:280193; MARPAT 142:280193

GI



I



II

AB The present invention relates to novel title compds. I (R1, R2 = independently H, OH, CN, C1-6 alkyl, C1-6 alkoxy, CF3, NR4R4'; R3 = H, C1-6 alkyl; X = 5-membered heterocycle optionally substituted with C1-4 alkyl containing at least 2-3 N, O, or S atoms wherein at least one heteroatom is N; Y = S, CR5:N, N:CR5; R4 = H, COR6, SO2R7, C1-6 alkyl; R4' = H, C1-6 alkyl; R5 = H or forms bond with X; R6 = H, C1-6 alkyl; R7 = H, C1-6 alkyl; n = 2-7) or a pharmaceutical salt thereof, as well as methods and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide. Thus,condensation of ClCO(CH2)4CO2Me with 2-picolinylhydrazide and subsequent cyclocondensation and saponification gave oxadiazole II. Formulations of prepared compds. I for oral delivery of glucagon like peptide-1 derivs. and melanocortin 4 receptor agonist peptides are given.

IT 847268-03-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heterocyclylalkanoic acid derivs. for oral delivery of glucagon like peptide-1 compound or melanocortin 4 receptor agonist peptide)

RN 847268-03-5 CAPLUS

CN 2-Oxazolepentanoic acid, 4-(3-thienyl)-, methyl ester (CA INDEX NAME)



IT 847268-04-6P 847268-05-7P 847268-07-9P 847268-10-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclylalkanoic acid derivs. for oral delivery of glucagon like peptide-1 compound or melanocortin 4 receptor agonist peptide)

RN 847268-04-6 CAPLUS
CN 2-Oxazolepentanoic acid, 4-(3-thienyl)- (CA INDEX NAME)



RN 847268-05-7 CAPLUS
CN 2-Oxazolepentanoic acid, 4-(2-thienyl)- (CA INDEX NAME)



RN 847268-07-9 CAPLUS
CN 2-Oxazolepentanoic acid, 4-(3-hydroxy-2-thienyl)- (CA INDEX NAME)



RN 847268-10-4 CAPLUS
CN 2-Oxazolepropanoic acid, 4-(3-hydroxy-2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:74117 CAPLUS Full-text
DOCUMENT NUMBER: 142:176828
TITLE: Preparation of 2-acylaminothiazole derivatives or salts thereof for treating thrombopenia
INVENTOR(S): Sugasawa, Keizo; Koga, Yuji; Obitsu, Kazuyoshi; Okuda, Takao; Harada, Koichiro; Kubota, Hideki; Hirayama, Fukushi; Abe, Masaki; Suzuki, Kenichi
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007651	A1	20050127	WO 2004-JP10440	20040715 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2529686	A1	20050127	CA 2004-2529686	20040715 <--
JP 2005047905	A	20050224	JP 2004-208207	20040715 <--
EP 1647553	A1	20060419	EP 2004-747829	20040715 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20060194844	A1	20060831	US 2004-564520	20040715 <--
CN 1835948	A	20060920	CN 2004-80020497	20040715 <--
IN 2005DN06145	A	20070824	IN 2005-DN6145	20051229 <--
MX 2006PA00441	A	20060405	MX 2006-PA441	20060111 <--
PRIORITY APPLN. INFO.:			JP 2003-275718 A	20030717 <--
			WO 2004-JP10440 W	20040715

OTHER SOURCE(S): MARPAT 142:176828
GI



I



II

AB A blood platelet-increasing drug comprising a compound of formula [I; A = lower alkylene; R1 = R11R12N; R11 = each (un)substituted lower alkyl or cycloalkyl; provided that when A is methylene, R11 is methylene which bridges R2 being thienyl or Ph or R11 is (un)substituted lower alkylene which forms a ring by being linked to A being methylene; R12 = each (un)substituted lower alkyl, cycloalkyl, or nonarom. heterocyclyl; R2 = each (un)substituted thienyl or Ph; R3 = each (un)substituted aromatic heterocyclyl, aryl, or cyclic amino] or a salt thereof as an active ingredient is provided. The 2-

acylaminothiazole derivs. have an activity of increasing platelets based on excellent effects of proliferating human c-Mpl-Ba/F3 cells and promoting megakaryoblast colony formation and are useful in treating thrombopenia (thrombocytopenia). For example, N-(2- thiazolyl)pyridine-3-carboxamide derivative (II) in vitro at 4.3 nM promoted the proliferation of human c-Mpl-Ba/F3 cells with efficacy higher (114%) than that of rhTPO (110% at 0.012 nM).

IT 832088-23-0P 832088-24-1P 832088-56-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-acylaminothiazole derivs. or salts thereof as blood platelet-increasing agents for treating thrombopenia)

RN 832088-23-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-amino-4-(4-chloro-2-thienyl)-, methyl ester (CA INDEX NAME)



RN 832088-24-1 CAPLUS
CN 5-Thiazoleacetic acid, 2-amino-4-(4-chloro-2-thienyl)- (CA INDEX NAME)



RN 832088-56-9 CAPLUS
CN 5-Thiazoleacetic acid, 2-amino-4-(4-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:220301 CAPLUS Full-text
DOCUMENT NUMBER: 140:270550
TITLE: A preparation of 1,3-diamino-2-hydroxypropane derivatives as beta-secretase enzyme inhibitors
INVENTOR(S): Fobian, Yvette M.; Freskos, John N.; Jagodzinska,

Barbara
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn
SOURCE: PCT Int. Appl., 535 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022523	A2	20040318	WO 2003-US28116	20030908 <--
WO 2004022523	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497979	A1	20040318	CA 2003-2497979	20030908 <--
AU 2003268550	A1	20040329	AU 2003-268550	20030908 <--
US 20040214890	A1	20041028	US 2003-657567	20030908 <--
US 7294642	B2	20071113		
EP 1534693	A2	20050601	EP 2003-749520	20030908 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014071	A	20050705	BR 2003-14071	20030908 <--
JP 2005538162	T	20051215	JP 2004-534764	20030908 <--
CN 1732161	A	20060208	CN 2003-824884	20030908 <--
NO 2005001189	A	20050510	NO 2005-1189	20050304 <--
MX 2005PA02508	A	20050603	MX 2005-PA2508	20050304 <--
IN 2005KN00441	A	20060127	IN 2005-KN441	20050316 <--
ZA 2005002755	A	20060222	ZA 2005-2755	20050405 <--
PRIORITY APPLN. INFO.:			US 2002-408783P P	20020906 <--
			WO 2003-US28116 W	20030908 <--

OTHER SOURCE(S): MARPAT 140:270550
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to diamino(hydroxy)propane derivs. of formula I [wherein: R1 = -(CH2)1-2-S(O)0-2-(C1-6 alkyl) or (un)substituted (cyclo)alkyl, alk(en/yn)yl, (hetero)aryl, etc.; R2 = H, C1-6 alkyl optionally substituted with 1-3 substituents, (CH2)0-4-(hetero)aryl, C2-6 alk(en/yn)yl, etc.; R3 = H, C1-6 alkyl optionally substituted with 1-3 substituents, (CH2)0-4-(hetero)aryl, etc.; R4 = C1-10 alkyl optionally substituted with 1-3 substituents, -(CH2)0-3-cycloalkyl, -(CR7R8)0-4-(hetero)aryl, etc.; one of R5 and R6 is H and the other is -C(O)(CR9R10)1-6-X-R11, etc.; R7 and R8 are independently selected from H, alkyl, hydroxyalkyl, alk(en/yn)yl, etc.; R9 and R10 are independently selected from H or C1-10 alkyl; R11 = (hetero)aryl, optionally substituted C1-10 alkyl, or C3-8 cycloalkyl, etc.; X = O, S, SO2, etc.]. Compds. I include inhibitors of beta-secretase enzyme useful in the treatment of Alzheimer's disease and other diseases characterized by

deposition of A beta-peptide in a mammal. Biol. examples include beta-secretase inhibition, assays using synthetic oligopeptide-substrates, inhibition of A beta production in human patients, etc. For instance, compound II (preparation 8) was prepared via amidation of benzoic acid derivative III by diamino(hydroxy)propane derivative IV and subsequent Boc-cleavage (no yield data). Using 19F-NMR an intramol. acyl-migration was observed when compound II was dissolved in DMSO-d6 and pH 4 buffer solution was added.

IT 674321-26-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diamino(hydroxy)propane derivs. useful as beta-secretase inhibitors)

RN 674321-26-7 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 3-(2-thienyl)-, (1R,2S)-2-amino-3-(3,5-difluorophenyl)-1-[[[(3-ethylphenyl)methyl]amino]methyl]propyl ester (CA INDEX NAME)

Absolute stereochemistry.



L23 ANSWER 4 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:143126 CAPLUS Full-text

DOCUMENT NUMBER: 140:199331

TITLE: Preparation of five-membered heterocyclic compounds as mGluR5 receptor antagonists

INVENTOR(S): Wensbo, David; Xin, Tao; Stefanac, Tomislav; Arora, Jalaj; Edwards, Louise; Isaac, Methvin; Slassi, Abdelmalik; Stormann, Thomas M.; McLeod, Donald A.; Kers, Annika; Malmberg, Johan; Oscarsson, Karin; Gyback, Helena; Johansson, Martin; Minidis, Alexander; Waldman, Mangus; Yngve, Ulrika; Osterwall, Christoffer

PATENT ASSIGNEE(S): Astra Zeneca Ab, Swed.; NPS Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 318 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014881	A2	20040219	WO 2003-US24846	20030808 <--

WO 2004014881	A3	20040527			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2494987	A1	20040219	CA 2003-2494987		20030808 <--
AU 2003259068	A1	20040225	AU 2003-259068		20030808 <--
US 20040152699	A1	20040805	US 2003-637012		20030808 <--
EP 1529045	A2	20050511	EP 2003-785036		20030808 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013265	A	20050705	BR 2003-13265		20030808 <--
JP 2006503009	T	20060126	JP 2004-527872		20030808 <--
CN 1894241	A	20070110	CN 2003-823845		20030808 <--
ZA 2005000886	A	20060726	ZA 2005-886		20050131 <--
IN 2005DN00486	A	20070119	IN 2005-DN486		20050208 <--
MX 2005PA01594	A	20050920	MX 2005-PA1594		20050209 <--
NO 2005001225	A	20050509	NO 2005-1225		20050309 <--
US 20060122397	A1	20060608	US 2005-274611		20051114 <--
PRIORITY APPLN. INFO.:			US 2002-402040P	P	20020809 <--
			US 2003-637012	B3	20030808 <--
			WO 2003-US24846	W	20030808 <--

OTHER SOURCE(S): MARPAT 140:199331

GI



I



II

AB The present invention relates to five-membered heterocyclic compds. (shown as I; variables defined below; e.g. II), a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compds. and to the use of said compds. in therapy, e.g. neurol., psychiatric and chronic and acute pain disorders (no data). Typical IC50 values for mGluR5 receptor antagonist activity are ≤10 μM; no values for individual compds. are given. Methods of preparation are claimed and example prepns. and/or characterization data are included for .apprx.800 examples of I and intermediates. For example, [3-[3-[[[4-methyl-5-(thiophen-2-yl)-4H-[1,2,4]triazol -3-yl]sulfanyl]methyl][1,2,4]oxadiazol-5-yl]phenyl]carbamic

acid tert-Bu ester was prepared in 79% yield by condensation of 4-methyl-5-(thiophen-2-yl)-4H-[1,2,4]triazole-3-thiol with [3-(3-chloromethyl-[1,2,4]oxadiazol-5-yl)phenyl]carbamic acid tert-Bu ester in MeCN in the presence of K2CO3. For I: P = H, C3-7alkyl or a 3- to 8-membered ring containing ≥1 atoms = C, N, O and S, which ring may optionally be fused with a 5- or 6-membered ring containing ≥1 C, N, O and S; R1 = H, hydroxy, halo, nitro, C1-6-alkylhalo, OC1-6alkylhalo, C1-6alkyl, OC1-6alkyl, C2-6alkenyl, OC2-6alkenyl, C2-6alkynyl, OC2-6alkynyl, C0-6alkylC3-6cycloalkyl, etc. and a 5- or 6-membered ring containing ≥1 C, N, O and S, wherein said ring may be substituted by ≥1 A. M1 = a bond, C1-3alkyl, C2-3alkenyl, C2-3alkynyl, C0-4alkyl(CO)C0-4alkyl, C0-3alkylOC0-3alkyl, C0-3alkyl(CO)NR5, C0-3alkyl(CO)NR5C0-3alkyl, C0-4-alkylNR5, C0-3alkylSC0-3alkyl, etc.; R2 = H, hydroxy, C0-6alkylcyano, oxo, NR5, NOR5, C1-4alkylhalo, halo, C1-4alkyl, etc. X1, X2 and X3 = CR, CO, N, NR, O and S; R = H, C0-3alkyl, halo, C0-3alkylOR5, C0-3-alkylNR5R6, C0-3alkyl(CO)OR5, C0-3alkylNR5R6 and C0-3alkylaryl; M2 = a bond, C1-3alkyl, C3-7cycloalkyl, C2-3alkenyl, C2-3alkynyl, C0-4alkyl(CO)C0-4alkyl, C0-3alkylOC0-3alkyl, etc.; R3 = H, hydroxy, C0-6alkylcyano, oxo, NR, NOR5, C1-4alkylhalo, halo, C1-4alkyl, etc. X4 = C0-4alkylR5, C0-4alkyl(NR5R6), C0-4-alkyl(NR5R6):N, NR5C0-4alkyl(NR5R6):N, NOC0-4alkyl, C1-4alkylhalo, C, O, SO, SO2 and S; Q is a 5- or 6-membered ring containing ≥1 C, N, O and S, which group may optionally be fused with a 5- or 6-membered ring containing ≥1 C, N, O and S and which fused ring may be substituted by ≥1 A. R4 = H, hydroxy, C0-6alkylcyano, oxo, NR5, NOR5, C1-4alkylhalo, halo, C1-4alkyl, OC1-4alkyl, OC0-6alkylaryl, etc. and a 5- or 6-membered ring containing ≥1 atoms = C, N, O or S, wherein said ring may be substituted by ≥1 A; R5, R6 = H, OH, C1-6alkyl, etc.; A = H, OH, O, halo, nitro, C0-6alkylcyano, etc.; m = 0-4; and n = 0-3; addnl. details are given in the claims.

IT 660417-26-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of five-membered heterocyclic compds. as mGluR5 receptor antagonists)

RN 660417-26-5 CAPLUS

CN 4H-1,2,4-Triazole-4-acetic acid, 1,5-dihydro-3-(2-thienyl)-5-thioxo- (CA INDEX NAME)



L23 ANSWER 5 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:120847 CAPLUS Full-text

DOCUMENT NUMBER: 140:163701

TITLE: Preparation of substituted thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation

INVENTOR(S): Archer, Janet Ann; Bordogna, Walter; Bull, Richard James; Clark, David Edward; Dyke, Hazel Joan; Gill, Matthew Iain Andrew; Harris, Neil Victor; Van Den Heuvel, Marco; Price, Stephen

PATENT ASSIGNEE(S): Argenta Discovery Limited, UK

SOURCE: PCT Int. Appl., 218 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013130	A1	20040212	WO 2003-GB3168	20030724 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494114	A1	20040212	CA 2003-2494114	20030724 <--
AU 2003255724	A1	20040223	AU 2003-255724	20030724 <--
EP 1525199	A1	20050427	EP 2003-766437	20030724 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013371	A	20050705	BR 2003-13371	20030724 <--
CN 1684957	A	20051019	CN 2003-823154	20030724 <--
JP 2005539001	T	20051222	JP 2004-525525	20030724 <--
MX 2005PA01334	A	20050908	MX 2005-PA1334	20050202 <--
NO 2005001107	A	20050420	NO 2005-1107	20050301 <--
US 20060122234	A1	20060608	US 2005-522873	20051004 <--
PRIORITY APPLN. INFO.:			GB 2002-18040 A	20020802 <--
			GB 2003-10462 A	20030507 <--
			WO 2003-GB3168 W	20030724 <--

OTHER SOURCE(S): MARPAT 140:163701
GI



I



II

AB Thiophene-2-hydroxamic acids (shown as I; variables defined below; e.g. II) and corresponding N-oxides, pharmaceutically acceptable salts, solvates and prodrugs of such compds. and their use in the treatment of diseases associated with histone deacetylase enzymic activity (e.g. cancer, psoriasis, fibroproliferative disorders, smooth muscle cell proliferation disorders, etc.) are claimed. Although the methods of preparation are not claimed, >100 example prepns. are included. For example, 5-(2-methyl-5-trifluoromethyl-2H-pyrazol-3-yl)thiophene-2-carboxylic acid hydroxyamide was prepared in 96% yield deprotection of 5-(2-methyl-5- trifluoromethyl-2H-pyrazol-3-

yl)thiophene-2-carboxylic acid (tetrahydropyran-2-yloxy)amide in MeOH using p-toluenesulfonic acid; the reactant was prepared in 78% yield by amide formation of 5-[2-methyl-5-(trifluoromethyl)-2H-pyrazol-3-yl]thiophene-2-carboxylic acid with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine in DMF using diisopropylethylamine and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate. Histone deacetylase inhibitory activity is reported for 6 examples of I, e.g. IC50 0.062 μM for II; 5 of these were tested for their ability to reduce cell proliferation in 2 cell lines (MCF-7 and MDA-MB-231; human mammary gland adenocarcinoma), e.g. IC50 = 0.6 and 2.0 μM, resp. for II. For I: R1 = aryl or heteroaryl, each (un)substituted by ≥1 R3, alkylenedioxy, carboxy, cyano, halo, hydroxy, nitro, haloalkyl, haloalkoxy, -C(O)R3, -C(O)OR3, -C(:Z)NR4R5, -NR4R5, -NR6C(O)OR3, -NR6C(O)NR4R5, -NR6C(:Z)R3, -OC(O)NR4R5, -NR6SO2R3, -OR3, -OC(O)R3, -SH, -SR3, -SOR3, -SO2R3 and -SO2NR4R5; R2 = H, chloro, cyano, fluoro, alkoxy, alkyl, or haloalkyl; R3 = aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or R7; R4 and R5 = H, alkyl, alkenyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl, wherein said alkyl or alkenyl are (un)substituted by aryl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl; or the group -NR4R5 may form a cyclic amine; R6 = H or lower alkyl; R7 = alkyl, alkenyl and alkynyl, wherein said alkyl, alkenyl or alkynyl are (un)substituted by ≥1 aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, hydroxy, -C(:Z)NR4R5, -NR4R5, -NR6C(:Z)R8, -OC(O)NR4R5, -NR6C(O)OR8, -NR6C(O)NR4R5, -NR6SO2R8, -OR8, -SOR8, SO2R8 and -SO2NR4R5; R8 = alkyl, alkenyl or alkynyl, (un)substituted by ≥1 aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, hydroxy and halogen; or R8 = aryl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl; and Z is O or S.

IT 656227-30-4P, 5-[1-[(tert-Butoxycarbonyl)methyl]-1H-pyrazol-3-yl]thiophene-2-carboxylic acid methyl ester 656227-56-4P, 5-(1-Carboxymethyl-1H-pyrazol-3-yl)thiophene-2-carboxylic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiophene-2-hydroxamic acids as histone deacetylase inhibitors useful against disorders involving increased cell proliferation)

RN 656227-30-4 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 3-[5-(methoxycarbonyl)-2-thienyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 656227-56-4 CAPLUS
CN 1H-Pyrazole-1-acetic acid, 3-[5-(methoxycarbonyl)-2-thienyl]- (CA INDEX NAME)



L23 ANSWER 6 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:696876 CAPLUS Full-text
DOCUMENT NUMBER: 139:230781
TITLE: Preparation of azole compounds for prevention or treatment of diabetic neuropathy
INVENTOR(S): Sakai, Nozomu; Momose, Yu; Murase, Katsuhito; Hazama, Masatoshi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 307 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072554	A1	20030904	WO 2003-JP2217	20030227 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003211385	A1	20030909	AU 2003-211385	20030227 <--
JP 2003321460	A	20031111	JP 2003-50286	20030227 <--
EP 1486490	A1	20041215	EP 2003-742890	20030227 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050090534	A1	20050428	US 2004-505742	20040825 <--
US 7183276	B2	20070227		

PRIORITY APPLN. INFO.: JP 2002-53933 A 20020228 <--
WO 2003-JP2217 W 20030227 <--
OTHER SOURCE(S): MARPAT 139:230781
GI



I

AB The title compds. I [R1 is hydrogen, halogeno, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, optionally substituted hydroxyl, optionally substituted mercapto, or optionally substituted amino; A is optionally substituted cycloamino, etc.; B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is oxygen, sulfur, or optionally substituted nitrogen; and Y is a bond or a divalent acyclic hydrocarbon group] are prepared The

bioactivity of compds. of this invention was demonstrated. Formulations are given.

IT 595597-49-2P 595597-60-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azole compds. for prevention and treatment of diabetic neuropathy)

RN 595597-49-2 CAPLUS
CN 5-Oxazolepropanoic acid, 4-(4-chlorophenyl)-2-(2-thienyl)-, methyl ester (CA INDEX NAME)



RN 595597-60-7 CAPLUS
CN 5-Oxazolepropanoic acid, 4-(4-chlorophenyl)-2-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:591157 CAPLUS Full-text
DOCUMENT NUMBER: 139:149641
TITLE: Preparation of pyrimidinones as viral polymerase inhibitors
INVENTOR(S): Avolio, Salvatore; Colarusso, Stefania; Conte, Immacolata; Harper, Steven; Koch, Uwe; Malancona, Savina; Matassa, Victor Giulio; Narjes, Frank; Petrocchi, Alessia; Summa, Vincenzo
PATENT ASSIGNEE(S): Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Italy
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062211	A1	20030731	WO 2003-GB124	20030115 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2473508	A1	20030731	CA 2003-2473508		20030115 <--
EP 1470113	A1	20041027	EP 2003-700366		20030115 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005524627	T	20050818	JP 2003-562091		20030115 <--
US 20050130997	A1	20050616	US 2005-500971		20050216 <--
PRIORITY APPLN. INFO.:			GB 2002-1179	A	20020118 <--
			WO 2003-GB124	W	20030115 <--

OTHER SOURCE(S): MARPAT 139:149641
GI



I



II

AB Title compds. I [wherein Z = (un)substituted alkynyl, aryl, or heteroaryl; R1 = (un)substituted alkyl or (aryl)alkyl; R2 = H, (un)substituted alkyl, alkylcarbonyl, aryl, arylcarbonyl, heteroaryl, (aryl)alkyl, (heteroaryl)alkyl; R3 = H, alkyl, (heterocycloalkyl)alkyl, dialkylaminoalkyl, (alkylcarbonyloxy)alkyl, (cycloalkoxycarbonyloxy)alkyl; and their pharmaceutically acceptable salts] were prepared as inhibitors of viral polymerases, especially the hepatitis C virus (HCV) polymerase enzyme. For example, II was prepared from 3-nitrothiophene-2-carbonitrile (preparation given) by base-catalyzed nucleophilic addition of hydroxylamine, reaction with di-Me acetylenedicarboxylate in CH2Cl2, intramol. cyclocondensation in xylene, room temperature O-acylation with pivaloyl chloride in the presence of 4-DMAP, base-catalyzed N-methylation with di-Me sulfate for 1 h, hydrogenation over Pd/C, and reaction with ortho-chlorobenzyl isocyanate in dichloromethane. I

exhibited an IC50 value of 100 μM or less for inhibition of HCV polymerase. Thus, I and their pharmaceutical compns. are useful for treating or preventing an illness due to HCV (no data).

IT 572917-28-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrimidinones as viral polymerase inhibitors)

RN 572917-28-3 CAPLUS

CN 1,2,4-Oxadiazole-5-acetic acid, 2,5-dihydro-5-(methoxycarbonyl)-2-methyl-3-(3-nitro-2-thienyl)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:154251 CAPLUS Full-text

DOCUMENT NUMBER: 138:205069

TITLE: Preparation of 2H-phthalazin-1-ones as poly(ADP-ribose)polymerase inhibitors for treatment of cancer

INVENTOR(S): Beaton, Graham; Moree, Wilna J.; Rueter, Jaimie K.; Dahl, Russell S.; McElligott, David L.; Goldman, Phyllis; Demaggio, Anthony J.; Christenson, Erik; Herendeen, Dan; Fowler, Kerry W.; Huang, Danwen; Bertino, Jaimie A.; Bourdon, Lisa H.; Fairfax, David J.; Jiang, Qin; Reisch, Helge A.; Song, Ren Hua; Zhichkin, Pavel E.

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 229 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015785	A1	20030227	WO 2002-US26271	20020815 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,

NE, SN, TD, TG

CA 2456985	A1	20030227	CA 2002-2456985		20020815 <--
AU 2002331621	A1	20030303	AU 2002-331621		20020815 <--
US 20040087588	A1	20040506	US 2002-222749		20020815 <--
US 6924284	B2	20050802			
EP 1423120	A1	20040602	EP 2002-768596		20020815 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
CN 1568187	A	20050119	CN 2002-820219		20020815 <--
JP 2005501848	T	20050120	JP 2003-520744		20020815 <--
NZ 531245	A	20050930	NZ 2002-531245		20020815 <--
MX 2004PA01353	A	20041027	MX 2004-PA1353		20040212 <--
PRIORITY APPLN. INFO.:			US 2001-312540P	P	20010815 <--
			WO 2002-US26271	W	20020815 <--

OTHER SOURCE(S): MARPAT 138:205069

GI



I



II

AB Title compds. and derivs. thereof I [wherein Q1 and Q2 = independently N or CRa; Ra = H, halo, NO2, or alkyl; R = H, alkyl, or N-protecting group; Y = NR1R2, R3C(=X1)Y1, (alkylene)x-NR11R12NR13[C(=X3)]c(NR14)d(R15)e[C(=X4)]fR16, or NR11R12N=CR20R21; R1, R14, and R20 = independently H or alkyl; R2 = arylcarbonyl, heteroalkyl, cyclo(alkyl), alkenyl, alkynyl, etc.; R3 = alkylene; X1, X3, and X4 = independently O or S; Y1 = NR4R5; R4 = H, (hetero)alkyl, or aralkyl; R5 = (un)substituted aralkyl, heteroalkyl, heterocyclyl, heteroaryl(alkyl), arylsulfonylamino, etc.; x = 0-1; R11 = H, alkyl, or (un)substituted heteroaralkyl; R12 = (cyclo)alkylene, heteroalkylene, aralkylene, or arylene; or NR11R12 = (un)substituted heterocyclyl; c = 0-2; d-f = independently 0-1; R13 = H, alkyl, arylcarbamoylalkylene, etc.; R15 = (hetero)alkylene or alkenylene; R16 = H, (un)substituted (hetero)aryl, (hetero)alkyl, cycloalkyl, aralkoxy, amino, arylsulfonylamino, etc.; R21 = alkyl, or substituted heteroaryl; and pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof] were prepared as poly(ADP-ribose)polymerase (PARP) inhibitors (no data). For example, condensation of 1,3-propanediamine with phthalic anhydride in EtOH gave 3,4-dihydropyrimido[1,2-a]indol-10(2H)-one, which was dissolved in ethylene glycol and reacted with NH2NH2•H2O to afford II (51%). I are useful for radiosensitizing and chemosensitizing tumor cells for the treatment of cancer (no data).

IT 500025-29-6P, 3-[3-(Thiophen-2-yl)-1,2,4-oxadiazol-5-yl]propionic acid 500025-30-9P, 3-[3-(Thiophen-3-yl)-1,2,4-oxadiazol-5-yl]propionic acid 500025-35-4P, 3-[3-(5-Nitrothiophen-3-yl)-1,2,4-oxadiazol-5-yl]propionic acid 500025-38-7P, 3-[3-[5-(tert-Butoxycarbonylamino)thiophen-3-yl]-1,2,4-oxadiazol-5-yl]propionic acid 500025-69-4P, Methyl 3-[3-[2-(tert-butoxycarbonylamino)thiophen-4-yl]-1,2,4-oxadiazol-5-yl]propionate 500025-70-7P, Methyl 3-[3-[2-(tert-butoxycarbonylamino)thiophen-5-yl]-1,2,4-oxadiazol

-5-yl]propionate 500025-79-6P, 3-[4-[5-(2-Carbomethoxyethyl)-1,2,4-oxadiazol-3-yl]thiophen-2-yl]-1-isobutylurea 500025-80-9P, Methyl 3-[3-[2-(Ethanesulfonylamino)thiophene-4-yl]-1,2,4-oxadiazol-5-yl]propionate 500026-08-4P, Methyl 3-[3-(5-benzyloxycarbonylaminothiophen-2-yl)-1,2,4-oxadiazol-5-yl]propionate 500026-09-5P, 3-[3-(5-Ethoxycarbonylaminothiophen-3-yl)-1,2,4-oxadiazol-5-yl]propionic acid methyl ester 500026-10-8P, 3-[3-(5-Propionylaminothiophen-3-yl)-1,2,4-oxadiazol-5-yl]propionic acid methyl ester 500026-11-9P, 3-[3-[5-(3-Methylbutyrylamino)thiophen-3-yl]-1,2,4-oxadiazol-5-yl]propionic acid methyl ester 500026-12-0P, 3-[3-(5-Benzyloxycarbonylaminothiophen-3-yl)-1,2,4-oxadiazol-5-yl]propionic acid methyl ester 500026-18-6P, 3-[3-(2-Propionylaminothiophene-4-yl)-1,2,4-oxadiazol-5-yl]propionic acid 500026-19-7P, 3-[3-[2-(3-Methylbutyrylamino)thiophen-4-yl]-1,2,4-oxadiazol-5-yl]propionic acid 500026-20-0P, 3-[3-(2-Benzyloxycarbonylaminothiophen-5-yl)-1,2,4-oxadiazol-5-yl]propionic acid 500026-21-1P, 3-[3-(2-Benzyloxycarbonylaminothiophen-4-yl)-1,2,4-oxadiazol-5-yl]propionic acid 500026-44-8P, 3-[3-(5-Ethoxycarbonylaminothiophen-3-yl)-1,2,4-oxadiazol-5-yl]propionic acid 500026-45-9P, 3-[3-[2-(tert-Butoxycarbonylamino)thiophen-5-yl]-1,2,4-oxadiazol-5-yl]propionic acid 500026-46-0P, 3-[4-[5-(2-Carboxyethyl)-1,2,4-oxadiazol-3-yl]thiophen-2-yl]-1-isobutylurea 500026-47-1P, 3-[3-[2-(Ethanesulfonylamino)thiophene-4-yl]-1,2,4-oxadiazol-5-yl]propionic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phthalazinone PARP inhibitors for treatment of cancer)

RN 500025-29-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-(2-thienyl)- (CA INDEX NAME)



RN 500025-30-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-(3-thienyl)- (CA INDEX NAME)



RN 500025-35-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-(5-nitro-3-thienyl)- (CA INDEX NAME)



RN 500025-38-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[(1,1-dimethylethoxy)carbonyl]amino]-3-thienyl]- (CA INDEX NAME)



RN 500025-69-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[(1,1-dimethylethoxy)carbonyl]amino]-3-thienyl]-, methyl ester (CA INDEX NAME)



RN 500025-70-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[(1,1-dimethylethoxy)carbonyl]amino]-2-thienyl]-, methyl ester (CA INDEX NAME)



RN 500025-79-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[[(2-methylpropyl)amino]carbonyl]amino]-3-thienyl]-, methyl ester (CA INDEX NAME)



RN 500025-80-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[(ethylsulfonyl)amino]-3-thienyl]-, methyl ester (CA INDEX NAME)



RN 500026-08-4 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[(phenylmethoxy)carbonyl]amino]-2-thienyl]-, methyl ester (CA INDEX NAME)



RN 500026-09-5 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[(ethoxycarbonyl)amino]-3-thienyl]-, methyl ester (CA INDEX NAME)



RN 500026-10-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[(1-oxopropyl)amino]-3-thienyl]-, methyl ester (CA INDEX NAME)



RN 500026-11-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[(3-methyl-1-oxobutyl)amino]-3-thienyl]-, methyl ester (CA INDEX NAME)



RN 500026-12-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[(phenylmethoxy)carbonyl]amino]-3-thienyl]-, methyl ester (CA INDEX NAME)



RN 500026-18-6 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[(1-oxopropyl)amino]-3-thienyl]- (CA INDEX NAME)



RN 500026-19-7 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[(3-methyl-1-oxobutyl)amino]-3-thienyl]- (CA INDEX NAME)



RN 500026-20-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[(phenylmethoxy)carbonyl]amino]-2-thienyl]- (CA INDEX NAME)



RN 500026-21-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[(phenylmethoxy)carbonyl]amino]-3-thienyl]- (CA INDEX NAME)



RN 500026-44-8 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[(ethoxycarbonyl)amino]-3-thienyl]- (CA INDEX NAME)



RN 500026-45-9 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[(1,1-dimethylethoxy)carbonyl]amino]-2-thienyl]- (CA INDEX NAME)



RN 500026-46-0 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[[[(2-methylpropyl)amino]carbonyl]amino]-3-thienyl]- (CA INDEX NAME)



RN 500026-47-1 CAPLUS
CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[5-[(ethylsulfonyl)amino]-3-thienyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 9 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:813909 CAPLUS Full-text
DOCUMENT NUMBER: 137:325416
TITLE: Preparation of substituted imidazoles/oxazoles /thiazoles as large conductance calcium-activated K channel openers
INVENTOR(S): Hongu, Mitsuya; Hosaka, Thoshihiro; Kashiwagi, Toshihiko; Kono, Rikako; Kobayashi, Hiroyuki
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 302 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083111	A2	20021024	WO 2002-JP3723	20020415 <--
WO 2002083111	A3	20040415		

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SG, SI, SK, TN, TT, UA, US, UZ, VN, YU, ZA
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,

GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2444596	A1	20021024	CA 2002-2444596	20020415 <--
AU 2002246397	A1	20021028	AU 2002-246397	20020415 <--
HU 2003003829	A2	20040301	HU 2003-3829	20020415 <--
HU 2003003829	A3	20060228		
CN 1503786	A	20040609	CN 2002-808370	20020415 <--
EP 1432690	A2	20040630	EP 2002-714577	20020415 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008956	A	20040713	BR 2002-8956	20020415 <--
JP 2004531522	T	20041014	JP 2002-580915	20020415 <--
JP 4073786	B2	20080409		
NZ 529043	A	20061130	NZ 2002-529043	20020415 <--
MX 2003PA09440	A	20040212	MX 2003-PA9440	20031015 <--
US 20040127527	A1	20040701	US 2004-474850	20040210 <--
AU 2005202751	A1	20050714	AU 2005-202751	20050623 <--
JP 2008044952	A	20080228	JP 2007-241012	20070918 <--

PRIORITY APPLN. INFO.:	JP 2001-116436	A	20010416 <--
	JP 2001-249671	A	20010820 <--
	AU 2002-246397	A3	20020415 <--
	JP 2002-580915	A3	20020415 <--
	WO 2002-JP3723	W	20020415 <--

OTHER SOURCE(S): MARPAT 137:325416

GI



I

AB The title compds. [I; X = NR4, O, S; R1, R2 = H, halo, CO2H, etc.; R3 = aryl, heterocyclyl, alkyl; R4 = H, alkyl], useful in the prophylaxis and/or treatment for pollakiuria or urinary incontinence, were prepared Thus, reacting 5-ethyl-2-iodo-4-(3-pyridyl)imidazole with 3-(hydroxymethyl)thiophene-2-boric acid in the presence of Pd(PPh3)4 and aqueous 2M Na2CO3 in dimethoxyethane afforded I.2HCl [X = NH; R1 = Et; R2 = 3-pyridyl; R3 = 3-(hydroxymethyl)thien-2-yl] which showed 100% inhibition time of 10-20 min in test on the rhythmic bladder contractions induced by substance P in anesthetized rats.

IT 473684-75-2P 473684-83-2P 473688-69-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazoles/oxazoles/thiazoles as large conductance calcium-activated K channel openers)

RN 473684-75-2 CAPLUS

CN 5-Oxazoleacetic acid, 2-(4-fluorophenyl)-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473684-83-2 CAPLUS
CN 5-Oxazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 473688-69-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(6-amino-3-pyridinyl)-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



IT 85162-09-0P 85162-11-4P 85162-12-5P
99923-84-9P 99923-87-2P 473683-12-4P
473683-26-0P 473684-63-8P 473684-77-4P
473684-85-4P 473684-89-8P 473684-91-2P
473684-93-4P 473685-07-3P 473685-09-5P
473685-52-8P 473685-54-0P 473685-56-2P
473685-58-4P 473685-64-2P 473685-66-4P
473685-68-6P 473685-70-0P 473685-72-2P
473685-74-4P 473685-75-5P 473685-80-2P
473685-84-6P 473685-86-8P 473685-88-0P
473685-90-4P 473685-93-7P 473685-95-9P
473685-97-1P 473686-01-0P 473686-03-2P
473686-05-4P 473686-07-6P 473686-09-8P
473686-14-5P 473686-16-7P 473686-18-9P
473686-20-3P 473686-22-5P 473686-44-1P
473686-63-4P 473686-65-6P 473686-67-8P
473686-71-4P 473686-73-6P 473686-75-8P
473686-79-2P 473686-85-0P 473686-87-2P
473686-91-8P 473686-95-2P 473686-97-4P
473686-99-6P 473687-03-5P 473687-05-7P

473687-07-9P 473687-11-5P 473687-13-7P
473687-15-9P 473687-17-1P 473687-19-3P
473687-21-7P 473687-25-1P 473687-27-3P
473687-29-5P 473687-31-9P 473687-33-1P
473687-35-3P 473687-91-1P 473687-93-3P
473687-95-5P 473687-97-7P 473688-02-7P
473688-03-8P 473688-11-8P 473688-13-0P
473688-15-2P 473688-16-3P 473688-21-0P
473688-23-2P 473688-48-1P 473688-50-5P
473688-54-9P 473688-57-2P 473688-64-1P
473688-71-0P 473688-74-3P 473688-76-5P
473688-79-8P 473688-81-2P 473688-86-7P
473688-93-6P 473688-96-9P 473688-99-2P
473689-02-0P 473689-25-7P 473689-27-9P
473689-29-1P 473689-31-5P 473689-34-8P
473689-36-0P 473689-38-2P 473689-40-6P
473689-42-8P 473689-44-0P 473689-48-4P
473689-50-8P 473689-54-2P 473689-60-0P
473689-62-2P 473689-64-4P 473689-66-6P
473689-68-8P 473689-70-2P 473689-72-4P
473689-76-8P 473689-78-0P 473689-80-4P
473689-82-6P 473689-84-8P 473689-86-0P
473689-88-2P 473689-91-7P 473689-92-8P
473689-93-9P 473689-94-0P 473689-95-1P
473689-97-3P 473690-00-5P 473690-03-8P
473690-07-2P 473690-12-9P 473690-14-1P
473690-16-3P 473690-18-5P 473690-20-9P
473690-23-2P 473690-25-4P 473690-27-6P
473690-28-7P 473690-29-8P 473690-32-3P
473690-34-5P 473690-36-7P 473690-38-9P
473690-40-3P 473690-42-5P 473690-44-7P
473690-46-9P 473690-48-1P 473690-50-5P
473690-52-7P 473690-54-9P 473690-58-3P
473690-59-4P 473690-60-7P 473690-61-8P
473690-62-9P 473690-64-1P 473690-69-6P
473690-71-0P 473690-75-4P 473690-77-6P
473690-79-8P 473690-83-4P 473690-85-6P
473690-87-8P 473690-89-0P 473690-93-6P
473690-95-8P 473690-97-0P 473690-99-2P
473691-01-9P 473691-05-3P 473691-09-7P
473691-11-1P 473691-15-5P 473691-32-6P
473691-34-8P 473691-36-0P 473691-38-2P
473691-40-6P 473691-42-8P 473691-46-2P
473691-48-4P 473691-58-6P 473691-60-0P
473691-62-2P 473691-64-4P 473691-66-6P
473691-68-8P 473691-70-2P 473691-72-4P
473691-74-6P 473691-76-8P 473691-80-4P
473691-86-0P 473691-90-6P 473691-93-9P
473691-97-3P 473691-98-4P 473692-00-1P
473692-01-2P 473692-07-8P 473692-12-5P
473692-13-6P 473692-14-7P 473692-16-9P
473692-17-0P 473692-18-1P 473692-19-2P
473692-20-5P 473692-21-6P 473692-22-7P
473692-23-8P 473692-29-4P 473692-30-7P
473692-31-8P 473692-32-9P 473692-33-0P
473692-34-1P 473692-36-3P 473692-37-4P
473692-38-5P 473692-39-6P 473692-40-9P
473692-41-0P 473692-42-1P 473692-47-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of imidazoles/oxazoles/thiazoles as large conductance calcium-activated K channel openers)

RN 85162-09-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-11-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-12-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)- (CA INDEX NAME)



RN 99923-84-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(2-thienyl)- (CA INDEX NAME)



RN 99923-87-2 CAPLUS

CN 4-Oxazoleacetic acid, 2-(4-methoxyphenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 473683-12-4 CAPLUS
CN 1H-Imidazole-4-acetic acid, 2-(5-chloro-2-thienyl)-5-(3-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 473683-26-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-chloro-2-thienyl)-5-(3-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 473684-63-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-chloro-2-thienyl)-5-(3-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 473684-77-4 CAPLUS
CN 5-Oxazoleacetic acid, 2-(4-fluorophenyl)-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473684-85-4 CAPLUS
CN 5-Oxazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473684-89-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methoxyphenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473684-91-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methoxyphenyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473684-93-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methylphenyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473685-07-3 CAPLUS
CN 1H-Imidazole-4-acetic acid, 2-(4-fluorophenyl)-5-(4-methyl-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-09-5 CAPLUS
CN 1H-Imidazole-4-acetic acid, 2-(4-fluorophenyl)-5-(4-methyl-2-thienyl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 473685-52-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methylphenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-54-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473685-56-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methylphenyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473685-58-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methoxyphenyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473685-64-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-66-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-methoxyphenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-68-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-[4-(1-methylethyl)phenyl]-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-70-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-benzofuranyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-72-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-74-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-isoquinolinyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-75-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-80-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-84-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-phenyl-, ethyl ester (CA INDEX NAME)



RN 473685-86-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chloro-4-methoxyphenyl)-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-88-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-90-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-[3-(acetyloxy)-4-methoxyphenyl]-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473685-93-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2,3-dihydro-5-benzofuranyl)-, ethyl ester (CA INDEX NAME)



RN 473685-95-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-, ethyl ester (CA INDEX NAME)



RN 473685-97-1 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(6-quinolinyl)-, ethyl ester (CA INDEX NAME)



RN 473686-01-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(6-chloro-3-pyridinyl)-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473686-03-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(6-chloro-3-pyridinyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473686-05-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-[2-(acetyloxy)phenyl]-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473686-07-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(methylthio)phenyl]-, ethyl ester (CA INDEX NAME)



RN 473686-09-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(1-methylethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 473686-14-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-3-thienyl)-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 473686-16-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(4-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473686-18-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(6-chloro-3-pyridinyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473686-20-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-[5-(hydroxymethyl)-4-methyl-2-thienyl]-, monosodium salt (9CI) (CA INDEX NAME)



RN 473686-22-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-[5-(1-hydroxyethyl)-2-thienyl]-, monosodium salt (9CI) (CA INDEX NAME)



RN 473686-44-1 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-bromo-2-thienyl)-2-(4-chlorophenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-63-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-65-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-bromo-2-thienyl)-2-(4-fluorophenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-67-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-4-methyl-2-thienyl)-2-(4-fluorophenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-71-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-73-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-75-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-79-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-methoxyphenyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-85-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-benzofuranyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-87-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-91-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-95-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-5-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-97-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473686-99-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(1-methylethyl)phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-03-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-05-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-naphthalenyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-07-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-hydroxyphenyl)-5-(2-thienyl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 473687-11-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-phenyl-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-13-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chloro-4-methoxyphenyl)-5-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-15-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(methylthio)phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-17-1 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2,3-dihydro-5-benzofuranyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-19-3 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-21-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(6-quinolinyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-25-1 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-3-thienyl)-2-(4-fluorophenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-27-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(5-chloro-3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-29-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(4-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-31-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-hydroxy-3-methoxyphenyl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 473687-33-1 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(3-hydroxy-4-methoxyphenyl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 473687-35-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-[4-(1-methylethyl)phenyl]-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473687-91-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(5-formyl-4-methyl-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473687-93-3 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-acetyl-2-thienyl)-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 473687-95-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-bromo-2-thienyl)-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 473687-97-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-4-methyl-2-thienyl)-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 473688-02-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-[3-(hydroxymethyl)-4-methyl-2-thienyl]-, ethyl ester (CA INDEX NAME)



RN 473688-03-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-[5-(1-hydroxyethyl)-2-thienyl]-, ethyl ester (CA INDEX NAME)



RN 473688-11-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 473688-13-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473688-15-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473688-16-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(3-thienyl)-, methyl ester (CA INDEX NAME)



RN 473688-21-0 CAPLUS
CN 4-Oxazolepropanoic acid, 2-(4-fluorophenyl)-5-(2-thienyl)-, sodium salt

(9CI) (CA INDEX NAME)



RN 473688-23-2 CAPLUS
CN 4-Oxazolepropanoic acid, 5-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473688-48-1 CAPLUS
CN 1H-Imidazole-4-acetic acid, 2-benzo[b]thien-2-yl-5-(5-chloro-2-thienyl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 473688-50-5 CAPLUS
CN 1H-Imidazole-4-acetic acid, 5-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, monosodium salt (9CI) (CA INDEX NAME)



RN 473688-54-9 CAPLUS
CN 1H-Imidazole-4-acetic acid, 5-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 473688-57-2 CAPLUS
CN 1H-Imidazole-4-acetic acid, 5-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, monosodium salt (9CI) (CA INDEX NAME)



RN 473688-64-1 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-imidazo[1,2-a]pyridin-6-yl-, ethyl ester (CA INDEX NAME)



RN 473688-71-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2,3-dihydro-1H-indol-5-yl)-, ethyl ester (CA INDEX NAME)



RN 473688-74-3 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 473688-76-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[2-(ethylmethylamino)-5-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 473688-79-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473688-81-2 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[2-(ethylmethylamino)-5-pyrimidinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473688-86-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-[6-(methylthio)-3-pyridinyl]-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473688-93-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-[6-(methylthio)-3-pyridinyl]-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473688-96-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(6-ethoxy-3-pyridinyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473688-99-2 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(6-methoxy-3-pyridinyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473689-02-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(6-methoxy-3-pyridinyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473689-25-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(2-thienyl)-2-[4-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 473689-27-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-fluoro-4-methoxyphenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-29-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-methylphenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-31-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(dimethylamino)phenyl]-, ethyl ester (CA INDEX NAME)



RN 473689-34-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-benzothiazolyl)-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-36-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[2-(methylthio)-5-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 473689-38-2 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2-quinolinyl)-, ethyl ester (CA INDEX NAME)



RN 473689-40-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[3-(dimethylamino)phenyl]-, ethyl ester (CA INDEX NAME)



RN 473689-42-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-thieno[3,2-b]pyridin-2-yl-, ethyl ester (CA INDEX NAME)



RN 473689-44-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1-methyl-1H-indol-2-yl)-, ethyl ester (CA INDEX NAME)



RN 473689-48-4 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1,2,3,4-tetrahydro-1-methyl-6-quinolinyl)-, ethyl ester (CA INDEX NAME)



RN 473689-50-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1H-indol-2-yl)-, ethyl ester (CA INDEX NAME)



RN 473689-54-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-60-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(4-chlorophenyl)-2-(4,5-dimethyl-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-62-2 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(5,6-dihydro-4H-cyclopenta[b]thien-2-yl)-, ethyl ester (CA INDEX NAME)



RN 473689-64-4 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2-quinoxalinyl)-, ethyl ester (CA INDEX NAME)



RN 473689-66-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2,3-dihydro-1-methyl-1H-indol-5-yl)-, ethyl ester (CA INDEX NAME)



RN 473689-68-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(6-methyl-3-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 473689-70-2 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-(methoxymethyl)-3-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 473689-72-4 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-[(dimethylamino)methyl]-3-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 473689-76-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2-methyl-5-benzothiazolyl)-, ethyl ester (CA INDEX NAME)



RN 473689-78-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-benzofuranyl)-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-80-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-82-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-[4-(methylthio)phenyl]-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-84-8 CAPLUS

CN 4-Oxazoleacetic acid, 2-(4-methoxy-3-methylphenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-86-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(6-quinolinyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-88-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473689-91-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(5-methylbenzo[b]thien-2-yl)-, ethyl ester (CA INDEX NAME)



RN 473689-92-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(6-fluorobenzo[b]thien-2-yl)-, ethyl ester (CA INDEX NAME)



RN 473689-93-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-[(methylthio)methyl]phenyl]-, ethyl ester (CA INDEX NAME)



RN 473689-94-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(ethylthio)phenyl]-, ethyl ester (CA INDEX NAME)



RN 473689-95-1 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[3-(methylthio)phenyl]-, ethyl ester (CA INDEX NAME)



RN 473689-97-3 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(3,4-dihydro-2H-1-benzothiopyran-6-yl)-, ethyl ester (CA INDEX NAME)



RN 473690-00-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[5-(dimethylamino)-2-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 473690-03-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-[(dimethylamino)methyl]phenyl]-, ethyl ester (CA INDEX NAME)



RN 473690-07-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473690-12-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1-formyl-2,3-dihydro-1H-indol-5-yl)-, ethyl ester (CA INDEX NAME)



RN 473690-14-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-chloropyrazinyl)-5-(5-chloro-2-thienyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 473690-16-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-[4-[(acetyloxy)methyl]phenyl]-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473690-18-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-methylphenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473690-20-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-quinolinyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473690-23-2 CAPLUS
CN 4-Oxazoleacetic acid, 5-(2-thienyl)-2-[4-(trifluoromethyl)phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-25-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-fluoro-4-methoxyphenyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-27-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-methylphenyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-28-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-methylphenyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-29-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2-quinolinyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-32-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-benzofuranyl)-5-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-34-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(hydroxymethyl)phenyl]-, monosodium salt (9CI) (CA INDEX NAME)



RN 473690-36-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-38-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methoxy-3-methylphenyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-40-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-quinolinyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-42-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-[4-(methylthio)phenyl]-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-44-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(dimethylamino)phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-46-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(6-quinolinyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-48-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 473690-50-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-furo[2,3-b]pyridin-5-yl-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 473690-52-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[2-(methylthio)-5-pyrimidinyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 473690-54-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-benzothiazolyl)-5-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-58-3 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-[(methylthio)methyl]phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-59-4 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(ethylthio)phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-60-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(5-methylbenzo[b]thien-2-yl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-61-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(6-fluorobenzo[b]thien-2-yl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-62-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(6-methyl-3-pyridinyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-64-1 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2,3-dihydro-1-methyl-1H-indol-5-yl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-69-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(3,4-dihydro-2H-1-benzothiopyran-6-yl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-71-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[3-(methylthio)phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-75-4 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2-methyl-5-benzothiazolyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-77-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2-quinoxalinyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-79-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[5-(dimethylamino)-2-pyridinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-83-4 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-[(dimethylamino)methyl]-3-pyridinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-85-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-(methoxymethyl)-3-pyridinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-87-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1,2,3,4-tetrahydro-1-methyl-6-quinolinyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-89-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1H-indol-2-yl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 473690-93-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-[(dimethylamino)methyl]phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-95-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1-methyl-1H-indol-5-yl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-97-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-thieno[3,2-b]pyridin-2-yl-, sodium salt (9CI) (CA INDEX NAME)



RN 473690-99-2 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[3-(dimethylamino)phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-01-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1-methyl-1H-indol-2-yl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-05-3 CAPLUS
CN 4-Oxazoleacetic acid, 5-(4-chlorophenyl)-2-(4,5-dimethyl-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-09-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-11-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-15-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(5,6-dihydro-4H-cyclopenta[b]thien-2-yl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-32-6 CAPLUS
CN 5-Oxazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 473691-34-8 CAPLUS
CN 5-Oxazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473691-36-0 CAPLUS
CN 5-Oxazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473691-38-2 CAPLUS
CN 5-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473691-40-6 CAPLUS
CN 5-Oxazoleacetic acid, 2-(4-methoxyphenyl)-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473691-42-8 CAPLUS
CN 5-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-4-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473691-46-2 CAPLUS
CN 5-Oxazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 473691-48-4 CAPLUS
CN 5-Oxazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 473691-58-6 CAPLUS
CN 5-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-4-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473691-60-0 CAPLUS
CN 5-Oxazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-4-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473691-62-2 CAPLUS
CN 5-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-4-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-64-4 CAPLUS
CN 5-Oxazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-66-6 CAPLUS
CN 5-Oxazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-68-8 CAPLUS
CN 5-Oxazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-70-2 CAPLUS
CN 5-Oxazoleacetic acid, 2-(4-methoxyphenyl)-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-72-4 CAPLUS
CN 5-Oxazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-4-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-74-6 CAPLUS
CN 5-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-76-8 CAPLUS
CN 5-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-4-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-80-4 CAPLUS
CN 5-Oxazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-86-0 CAPLUS
CN 5-Oxazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-90-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 473691-93-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473691-97-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-[6-(diethylamino)-3-pyridinyl]-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473691-98-4 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-(cyclopropylmethylamino)-3-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 473692-00-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-[6-(diethylamino)-3-pyridinyl]-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-01-2 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-(cyclopropylmethylamino)-3-pyridinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-07-8 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 473692-12-5 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[4-(methylthio)phenyl]-, ethyl ester (CA INDEX NAME)



RN 473692-13-6 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[4-(dimethylamino)phenyl]-, ethyl ester (CA INDEX NAME)



RN 473692-14-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-chlorophenyl)-4-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-16-9 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(6-ethoxy-3-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 473692-17-0 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(6-methoxy-3-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 473692-18-1 CAPLUS
CN 5-Thiazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-4-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-19-2 CAPLUS
CN 5-Thiazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-4-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-20-5 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-fluorophenyl)-4-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-21-6 CAPLUS
CN 5-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-4-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-22-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-methoxyphenyl)-4-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-23-8 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-methoxyphenyl)-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-29-4 CAPLUS
CN 5-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-4-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-30-7 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[2-(methylthio)-5-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 473692-31-8 CAPLUS
CN 5-Thiazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-32-9 CAPLUS
CN 5-Thiazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-33-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-fluorophenyl)-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-34-1 CAPLUS
CN 5-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-36-3 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 473692-37-4 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 473692-38-5 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-39-6 CAPLUS
CN 5-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-4-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-40-9 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(6-methoxy-3-pyridinyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-41-0 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-42-1 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[2-(methylthio)-5-pyrimidinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-47-6 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-fluorophenyl)-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



IT 473692-48-7P 473692-49-8P 473692-50-1P
473692-56-7P 473692-58-9P 473692-59-0P
473692-60-3P 473692-61-4P 473692-62-5P
473692-63-6P 473692-64-7P 473692-65-8P
473692-66-9P 473692-68-1P 473692-69-2P
473692-71-6P 473692-73-8P 473692-74-9P
473692-75-0P 473692-76-1P 473692-77-2P
473692-78-3P 473692-79-4P 473692-81-8P
473692-88-5P 473692-89-6P 473692-90-9P
473692-91-0P 473692-93-2P 473692-94-3P
473692-95-4P 473692-96-5P 473692-99-8P
473693-01-5P 473694-33-6P 473694-35-8P
473694-37-0P 473694-38-1P 473694-41-6P
473694-42-7P 473694-44-9P 473694-45-0P
473694-46-1P 473694-47-2P 473694-49-4P
473694-50-7P 473694-51-8P 473694-52-9P
473694-57-4P 473694-58-5P 473705-72-5P
473705-73-6P 473705-74-7P 473705-75-8P
473705-77-0P 473705-78-1P 473705-79-2P
473705-82-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazoles/oxazoles/thiazoles as large conductance calcium-activated K channel openers)

RN 473692-48-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-(4-methoxyphenyl)-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-49-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-50-1 CAPLUS
CN 5-Thiazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-56-7 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(6-ethoxy-3-pyridinyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-58-9 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-chlorophenyl)-4-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-59-0 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[4-(dimethylamino)phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-60-3 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[4-(methylthio)phenyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-61-4 CAPLUS
CN 5-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-62-5 CAPLUS
CN 5-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-4-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-63-6 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-fluorophenyl)-4-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-64-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-[2-(dimethylamino)-5-pyrimidinyl]-4-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-65-8 CAPLUS
CN 5-Thiazoleacetic acid, 2-[6-(dimethylamino)-3-pyridinyl]-4-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-66-9 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-methoxyphenyl)-4-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-68-1 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 473692-69-2 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-71-6 CAPLUS
CN 4-Thiazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 473692-73-8 CAPLUS
CN 4-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-74-9 CAPLUS
CN 4-Thiazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 473692-75-0 CAPLUS
CN 4-Thiazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 473692-76-1 CAPLUS
CN 4-Thiazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 473692-77-2 CAPLUS
CN 4-Thiazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-78-3 CAPLUS
CN 4-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-5-(5-chloro-2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-79-4 CAPLUS
CN 4-Thiazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-81-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-88-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[5-(dimethylamino)pyrazinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-89-6 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[5-(dimethylamino)pyrazinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 473692-90-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-imidazo[1,2-a]pyridin-6-yl-, sodium salt (9CI) (CA INDEX NAME)



RN 473692-91-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(2,3-dihydro-1H-indol-5-yl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 473692-93-2 CAPLUS
CN 1H-Imidazole-4-acetic acid, 5-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 473692-94-3 CAPLUS
CN 1H-Imidazole-4-acetic acid, 5-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 473692-95-4 CAPLUS
CN 1H-Imidazole-4-acetic acid, 5-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, ethyl ester (CA INDEX NAME)



RN 473692-96-5 CAPLUS
CN 1H-Imidazole-4-acetic acid, 2-benzo[b]thien-2-yl-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473692-99-8 CAPLUS
CN 4-Thiazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473693-01-5 CAPLUS
CN 4-Thiazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473694-33-6 CAPLUS
CN 5-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-4-(5-chloro-2-thienyl)- (CA INDEX NAME)



RN 473694-35-8 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 473694-37-0 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]- (CA INDEX NAME)



RN 473694-38-1 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]- (CA INDEX NAME)



RN 473694-41-6 CAPLUS
CN 5-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-4-(5-chloro-2-thienyl)- (CA INDEX NAME)



RN 473694-42-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[2-(dimethylamino)-5-pyrimidinyl]- (CA INDEX NAME)



RN 473694-44-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-5-(5-chloro-2-thienyl)- (CA INDEX NAME)



RN 473694-45-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(6-fluorobenzo[b]thien-2-yl)- (CA INDEX NAME)



RN 473694-46-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-benzo[b]thien-2-yl-5-(3-thienyl)- (CA INDEX NAME)



RN 473694-47-2 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-thieno[3,2-b]pyridin-2-yl- (CA INDEX NAME)



RN 473694-49-4 CAPLUS
CN 4-Thiazoleacetic acid, 2-benzo[b]thien-2-yl-5-(5-chloro-2-thienyl)- (CA INDEX NAME)



RN 473694-50-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[4-(methylthio)phenyl]- (CA INDEX NAME)



RN 473694-51-8 CAPLUS
CN 5-Oxazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 473694-52-9 CAPLUS

CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(5-chloro-2-thienyl)- (CA INDEX NAME)



RN 473694-57-4 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 473694-58-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1-methyl-1H-indol-2-yl)- (CA INDEX NAME)



RN 473705-72-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-benzofuranyl)-5-(5-chloro-3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473705-73-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-[4-(acetyloxy)-3-methoxyphenyl]-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473705-74-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473705-75-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-furo[2,3-b]pyridin-5-yl-, ethyl ester (CA INDEX NAME)



RN 473705-77-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(1-methyl-1H-indol-5-yl)-, ethyl ester (CA INDEX NAME)



RN 473705-78-1 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(4-methoxyphenyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 473705-79-2 CAPLUS
CN 4-Thiazoleacetic acid, 5-(5-chloro-2-thienyl)-2-[6-(dimethylamino)-3-pyridinyl]-, sodium salt (9CI) (CA INDEX NAME)



RN 473705-82-7 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-fluorophenyl)- (CA INDEX NAME)



IT 85162-04-5 473694-10-9 473694-14-3
473694-24-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazoles/oxazoles/thiazoles as large conductance calcium-activated K channel openers)

RN 85162-04-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473694-10-9 CAPLUS
CN 1H-Imidazole-4-acetic acid, 2-(5-chloro-3-thienyl)-5-(3-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 473694-14-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-formyl-4-methyl-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 473694-24-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



IT 473694-16-5P 473694-23-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazoles/oxazoles/thiazoles as large conductance calcium-activated K channel openers)
RN 473694-16-5 CAPLUS
CN 4-Oxazolepropanoic acid, 5-(5-chloro-2-thienyl)-2-(4-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 473694-23-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(6-azido-3-pyridinyl)-5-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



L23 ANSWER 10 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:487577 CAPLUS Full-text

DOCUMENT NUMBER: 137:63420
TITLE: Preparation of lactone ketolide macrolide erythromycin antibiotics
INVENTOR(S): Andreotti, Daniele; Arista, Luca; Biondi, Stefano; Cardullo, Francesca; Damiani, Frederica; Lociuro, Sergio; Marchioro, Carla; Merlo, Giancarlo; Mingardi, Anna; Niccolai, Daniela; Paio, Alfredo; Piga, Elisabetta; Pozzan, Alfonso; Seri, Catia; Tarsi, Luca; Terreni, Silvia; Tibasco, Jessica
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050091	A1	20020627	WO 2001-GB5665	20011220 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2432429	A1	20020627	CA 2001-2432429	20011220 <--
AU 2002017277	A	20020701	AU 2002-17277	20011220 <--
EP 1363925	A1	20031126	EP 2001-271380	20011220 <--
EP 1363925	B1	20061115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002526	A2	20031128	HU 2003-2526	20011220 <--
CN 1492874	A	20040428	CN 2001-822651	20011220 <--
BR 2001016431	A	20040622	BR 2001-16431	20011220 <--
JP 2004531471	T	20041014	JP 2002-551984	20011220 <--
NZ 526450	A	20050429	NZ 2001-526450	20011220 <--
AT 345350	T	20061215	AT 2001-271380	20011220 <--
ES 2275621	T3	20070616	ES 2001-271380	20011220 <--
IN 2003DN00933	A	20070420	IN 2003-DN933	20030616 <--
ZA 2003004748	A	20040423	ZA 2003-4748	20030619 <--
NO 2003002846	A	20030820	NO 2003-2846	20030620 <--
MX 2003PA05668	A	20041203	MX 2003-PA5668	20030620 <--
US 20040077557	A1	20040422	US 2003-450893	20031119 <--
US 20050215495	A1	20050929	US 2005-127701	20050512 <--
US 20060211636	A1	20060921	US 2006-422122	20060605 <--
PRIORITY APPLN. INFO.:			GB 2000-31309 A	20001221 <--
			GB 2001-26276 A	20011101 <--
			GB 2001-26277 A	20011101 <--
			WO 2001-GB5665 W	20011220 <--
			US 2003-450893 B1	20031119 <--
			US 2005-127701 A1	20050512

OTHER SOURCE(S): MARPAT 137:63420
GI



I

AB The present invention relates to lactone ketolides I wherein R is H, CN, substituted alkyl; R1 is alkyl, alkenyl; R2 is H, hydroxy protecting group; R3 is H, halogen, and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body. Thus, (11S,21R)-3-decladinosyl-11,12-dideoxy-6-O-methyl-3- oxo-12,11-[oxycarbonyl-(cyano)-methylene]erythromycin A was prepared and tested as antibacterial agent against Streptococcus pneumoniae and Streptococcus pyogenes (MIC ≤ 1 μg/mL).

IT 439106-58-8P 439106-59-9P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of lactone ketolide macrolide erythromycin antibiotics and their use in therapy or prophylaxis of systemic or topical bacterial infections)

RN 439106-58-8 CAPLUS
CN 1H-Imidazole-1-propanoic acid, 4-(2-thienyl)-, methyl ester (CA INDEX NAME)



RN 439106-59-9 CAPLUS
CN 1H-Imidazole-1-propanoic acid, 4-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



IT 439108-79-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of lactone ketolide macrolide erythromycin antibiotics and their use in therapy or prophylaxis of systemic or topical bacterial infections)
RN 439108-79-9 CAPLUS
CN 1,2,4-Oxadiazole-5-butanoic acid, 3-(5-nitro-3-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 11 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:391693 CAPLUS Full-text
DOCUMENT NUMBER: 136:401786
TITLE: Preparation of isoxazole derivatives for prevention and treatment of diabetes
INVENTOR(S): Momose, Yu; Maekawa, Tsuyoshi; Asakawa, Tomoko; Sakai, Nozomu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 270 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040458	A1	20020523	WO 2001-JP10001	20011116 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2429426	A1	20020523	CA 2001-2429426	20011116 <--
AU 2002015218	A5	20020527	AU 2002-15218	20011116 <--
JP 2002212171	A	20020731	JP 2001-352466	20011116 <--
EP 1340749	A1	20030903	EP 2001-983808	20011116 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040048908	A1	20040311	US 2003-416658	20030514 <--
US 7022725	B2	20060404		
US 20060084690	A1	20060420	US 2005-295058	20051206 <--

PRIORITY APPLN. INFO.: JP 2000-350869 A 20001117 <--
WO 2001-JP10001 W 20011116 <--
US 2003-416658 A3 20030514 <--

OTHER SOURCE(S): MARPAT 136:401786

GI



I

AB Described are preventives or remedies for diabetes containing compds. of the general formula (I) or their salts or prodrugs thereof [wherein one of R1 and R2 is hydrogen or a substituent and the other is an optionally substituted cyclic group; W is a free valency or a divalent aliphatic hydrocarbon group; and Y is a group represented by the general formula OR3 (wherein R3 is hydrogen, optionally substituted hydrocarbyl, an optionally substituted heterocyclic group, or optionally substituted acyl) or carboxyl which may be converted into an ester or an amide]. These compds. have excellent insulin secretion-promoting and blood sugar-decreasing effects and low toxicity and are useful as drugs, particularly preventive and therapeutic agents for diabetes and diabetic complication. Thus, reduction of 3-[5-(3,4-dichlorophenyl)-4-isoxazolyl]propionic acid Me ester (preparation given) by diisobutylaluminum hydride in hexane/THF at room temperature for 1 h gave 97% 3-[5-(3,4-chlorophenyl)-4-isoxazolyl]propanol (II). II at 30 mg/kg p.o. was administered to rats and after 60 min, the rats were fed with glucose at 2 g/kg p.o. After 30 min, the blood sample was taken and the blood sugar level measured was 75% of the control. A capsule and tablet formulation containing II were formulated.

IT 430530-17-9P 430530-18-0P 430530-77-1P
430530-78-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of isoxazole derivs. having insulin secretion promoting and blood sugar decreasing effects for prevention and treatment of diabetes and diabetes complication)

RN 430530-17-9 CAPLUS

CN 4-Isoxazolepropanoic acid, 5-(5-chloro-2-thienyl)- (CA INDEX NAME)



RN 430530-18-0 CAPLUS
CN 4-Isoxazolepropanoic acid, 5-(5-chloro-2-thienyl)-, methyl ester (CA INDEX NAME)



RN 430530-77-1 CAPLUS
CN 4-Isoxazolepropanoic acid, 5-(4,5-dichloro-2-thienyl)- (CA INDEX NAME)



RN 430530-78-2 CAPLUS
CN 4-Isoxazolepropanoic acid, 5-(4,5-dichloro-2-thienyl)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 12 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:171871 CAPLUS Full-text
DOCUMENT NUMBER: 136:232294
TITLE: Oxazolyl-aryloxyacetic acid derivatives and thiazole analogs and their use as PPAR agonists, e.g., as antidiabetics and hypolipidemics
INVENTOR(S): Brooks, Dawn Alisa; Connor, Scott Eugene; Dominianni, Samuel James; Godfrey, Alexander Glenn; Gossett, Lann Stacy; Rito, Christopher John; Tripp, Allie Edward; Warshawsky, Alan M.; Winneroski, Leonard Larry; Zhu, Guoxin
PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018355	A1	20020307	WO 2001-US22615	20010823 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420178	A1	20020307	CA 2001-2420178	20010823 <--
AU 2001084658	A	20020313	AU 2001-84658	20010823 <--
EP 1313715	A1	20030528	EP 2001-963732	20010823 <--
EP 1313715	B1	20070801		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509084	T	20040325	JP 2002-523473	20010823 <--
AT 368653	T	20070815	AT 2001-963732	20010823 <--
ES 2288982	T3	20080201	ES 2001-963732	20010823 <--
US 20040024034	A1	20040205	US 2003-343474	20030129 <--
US 6982278	B2	20060103		
US 20050250825	A1	20051110	US 2005-181640	20050714 <--
US 7351728	B2	20080401		

PRIORITY APPLN. INFO.:
US 2000-227233P P 20000823 <--
WO 2001-US22615 W 20010823 <--
US 2003-343474 A3 20030129 <--

OTHER SOURCE(S): MARPAT 136:232294
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title oxazoles I and their pharmaceutically acceptable salts, solvates, and hydrates are disclosed [wherein R1 = (un)substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl, or cycloalkyl-alkyl; R2 = H, alkyl, or haloalkyl; n = 2, 3, or 4, with the resultant polymethylene chain optionally containing a carbon-carbon double bond; W = O or S; Y = (un)substituted phenylene, naphthylene, or 1,2,3,4-tetrahydronaphthylene; R3 = H, alkyl, or haloalkyl; R4 = H, alkyl, haloalkyl or (un)substituted PhCH2; provided that when R3 = R4 = H, then R2 = alkyl or haloalkyl; R5 = H, alkyl, aminoalkyl]. Approx. 120 examples are given. One example of a thiazole analog is also given. The compds. are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus. For instance, 2-(3-bromophenyl)-4-(chloromethyl)-5-methyloxazole (prepared in 2 steps) underwent cyanation, hydrolysis to an acid, reduction to an alc., tosylation, and etherification with the corresponding phenol derivative to give intermediate bromide II. The latter compound underwent Pd-catalyzed ethynylation, hydrogenation of the ethynyl group, and alkaline hydrolysis, to give title compound III. This compound bound to human PPARα

and PPARγ receptors in vitro with IC50 values of 31 and 219 nM, resp., vs. values of 94,500 and 1180 for troglitazole, and 68,000 and 125,000 for fenofibric acid. At 30 mg/kg orally in mice (transgenic for human apoAI), III gave a 74.3% reduction in serum triglycerides and a 180% increase in high-d. lipoprotein cholesterol, vs. 41% and 48% for fenofibrate. III also gave complete normalization of blood glucose in diabetic mice at 30 mg/kg orally.

IT 403611-88-1P, (5-Methyl-2-(thiophen-2-yl)-4-oxazole)acetic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of oxazolyl-aryloxyacetic acid derivs. and thiazole analogs and their use as PPAR agonists)

RN 403611-88-1 CAPLUS

CN 4-Oxazoleacetic acid, 5-methyl-2-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 13 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:157745 CAPLUS Full-text

DOCUMENT NUMBER: 136:216740

TITLE: Preparation of oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists

INVENTOR(S): Brooks, Dawn Alisa; Godfrey, Alexander Glenn; Jones, Sarah Beth; McCarthy, James Ray; Rito, Christopher John; Winneroski, Leonard Larry, Jr.; Xu, Yanping

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 249 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016331	A1	20020228	WO 2001-US22616	20010823 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418104	A1	20020228	CA 2001-2418104	20010823 <--
AU 2001084659	A	20020304	AU 2001-84659	20010823 <--
EP 1313716	A1	20030528	EP 2001-963733	20010823 <--
EP 1313716	B1	20070502		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001013409	A	20030701	BR 2001-13409		20010823 <--
HU 2003000857	A2	20031028	HU 2003-857		20010823 <--
HU 2003000857	A3	20070328			
JP 2004506721	T	20040304	JP 2002-521432		20010823 <--
NZ 523804	A	20040924	NZ 2001-523804		20010823 <--
AT 361283	T	20070515	AT 2001-963733		20010823 <--
ES 2286137	T3	20071201	ES 2001-963733		20010823 <--
ZA 2003000570	A	20040421	ZA 2003-570		20030121 <--
US 20040097590	A1	20040520	US 2003-343476		20030129 <--
US 6930120	B2	20050816			
IN 2003KN00113	A	20050311	IN 2003-KN113		20030129 <--
NO 2003000729	A	20030402	NO 2003-729		20030214 <--
MX 2003PA01558	A	20030606	MX 2003-PA1558		20030220 <--
US 20050245584	A1	20051103	US 2005-54226		20050209 <--
US 7345070	B2	20080318			
PRIORITY APPLN. INFO.:			US 2000-227234P	P	20000823 <--
			WO 2001-US22616	W	20010823 <--
			US 2003-343476	A3	20030129 <--

OTHER SOURCE(S): CASREACT 136:216740; MARPAT 136:216740

GI



I



II

AB Title compds. [I; n = 2, 3, 4; W = CH2, CH(OH), CO, O; R1 = aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, (CH3)3C; R2 = H, alkyl haloalkyl, C6H5; Y = thiophen-2,5-diyl, phenylene; R3 = alkyl, haloalkyl; R4 = C6H5, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl, benzo[1,3]dioxol-5-yl; R5 = H, alkyl, aminoalkyl], stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof are prepared for modulating a peroxisome proliferator-activated receptor (PPAR), particularly in the treatment of diabetes mellitus, cardiovascular disease, and animal syndrome X disease. Thus, the title compound II was prepared and tested for activity of lowering triglyceride serum level in mice, at 41.3%.

IT 401791-29-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazolyl-arylpropionic acid derivs. and their use as PPAR agonists)

RN 401791-29-5 CAPLUS

CN 4-Oxazoleacetic acid, 5-methyl-2-(5-methyl-2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 14 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:357903 CAPLUS Full-text
DOCUMENT NUMBER: 137:78889
TITLE: Phosphine-Catalyzed Annulation of Thioamides and 2-Alkynoates: A New Synthesis of Thiazolines
AUTHOR(S): Liu, Bing; Davis, Roman; Joshi, Biren; Reynolds, Daniel W.
CORPORATE SOURCE: Chemical Development, GlaxoSmithKline, Research Triangle Park, NC, 27709-3398, USA
SOURCE: Journal of Organic Chemistry (2002), 67(13), 4595-4598
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:78889
AB The annulation of thioamides with 2-alkynoates and 2,3-dienoates under the catalysis of tri-n-butylphosphine was described. The annulation reaction provided a new entry to thiazolines, particularly those with 2-aryl substituents.
IT 440632-69-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(phosphine-catalyzed annulation of thioamides and 2-alkynoates in new synthesis of thiazolines)
RN 440632-69-9 CAPLUS
CN 5-Thiazoleacetic acid, 4,5-dihydro-2-(2-thienyl)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 15 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:146967 CAPLUS Full-text
DOCUMENT NUMBER: 139:36479
TITLE: Azlactone synthesis of 3-aryl(heteroaryl)pyrazole-4-acetic acids and their nitriles

AUTHOR(S): Vovk, M. V.; Chornous, V. O.; Tsimbal, I. F.; Bratenko, M. K.
CORPORATE SOURCE: Inst. Org. Khim., NAN Ukr., Kiev, Ukraine
SOURCE: Ukrainskii Khimicheskii Zhurnal (Russian Edition) (2002), 68(11-12), 59-64
CODEN: UKZHAU; ISSN: 0041-6045
PUBLISHER: Institut Obshchei i Neorganicheskoi Khimii im. V. I. Vernadskogo NAN Ukrainy
DOCUMENT TYPE: Journal
LANGUAGE: Ukrainian
OTHER SOURCE(S): CASREACT 139:36479
GI



I II III

AB (pyrazolylmethylene)oxazolones I [R = (un)substituted Ph, 2-thienyl] were prepared from pyrazolecarboxaldehydes and hippuric acid. Acid hydrolysis of I gave II, which were converted to pyrazole-4-acetic acids III (R1 = COOH) by H2O2 and to pyrazole-4-acetonitriles III (R1 = CN) by hydroxylamine and acetic anhydride.
IT 88696-85-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(3-aryl(heteroaryl)pyrazole-4-acetic acids and their nitriles from pyrazolecarboxaldehydes and hippuric acid via azlactones)
RN 88696-85-9 CAPLUS
CN 1H-Pyrazole-4-acetic acid, 1-phenyl-3-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 16 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:152678 CAPLUS Full-text
DOCUMENT NUMBER: 134:193433
TITLE: Preparation of oxazoles and thiazoles useful as neurotrophin production/secretion promoting agents
INVENTOR(S): Momose, Yu; Murase, Katsuhito
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014372	A2	20010301	WO 2000-JP5681	20000824 <--
WO 2001014372	A3	20020321		
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2382355	A1	20010301	CA 2000-2382355	20000824 <--
JP 2001131161	A	20010515	JP 2000-259390	20000824 <--
JP 3558588	B2	20040825		
JP 2002080467	A	20020319	JP 2001-205451	20000824 <--
BR 2000013493	A	20020514	BR 2000-13493	20000824 <--
EP 1206472	A1	20020522	EP 2000-954966	20000824 <--
EP 1206472	B1	20031001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 251156	T	20031015	AT 2000-954966	20000824 <--
HU 2003002046	A2	20031028	HU 2003-2046	20000824 <--
HU 2003002046	A3	20070328		
ES 2206292	T3	20040516	ES 2000-954966	20000824 <--
PT 1206472	T	20040630	PT 2000-954966	20000824 <--
AU 780307	B2	20050317	AU 2000-67276	20000824 <--
RU 2260003	C2	20050910	RU 2002-107321	20000824 <--
TW 268929	B	20061221	TW 2000-89117045	20000824 <--
SK 285938	B6	20071102	SK 2002-247	20000824 <--
US 6605629	B1	20030812	US 2001-868304	20010629 <--
MX 2001PA13453	A	20021122	MX 2001-PA13453	20011219 <--
ZA 2002001044	A	20030206	ZA 2002-1044	20020206 <--
NO 2002000831	A	20020424	NO 2002-831	20020220 <--
NO 322499	B1	20061016		
HK 1044762	A1	20040121	HK 2002-105926	20020813 <--

PRIORITY APPLN. INFO.:
JP 1999-238917 A 19990825 <--
JP 2000-259390 A3 20000824 <--
WO 2000-JP5681 W 20000824 <--

OTHER SOURCE(S): MARPAT 134:193433
GI



I

AB Neurotrophin production/secretion promoting agents which comprise an azole derivative I (e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole), wherein R1 = halogen, heterocyclic group, OH which may optionally be substituted, SH which may optionally be substituted, or an amino group which may optionally be substituted; A = acyl group,

heterocyclic group, OH which may optionally be substituted, or carboxyl group which may optionally be esterified or amidated; B = aromatic group; X = O, S, N which may optionally be substituted; and Y = divalent hydrocarbon group or heterocyclic group, or a salt thereof, pharmaceutical compns. containing I, and their uses as agents for preventing or treating neuropathy are claimed. I scarcely produce side effects and can be used as prophylactic/therapeutic agents for peripheral neuropathies (e.g. diabetic neuropathy, cancer therapy-induced neuropathy), diabetic cardiomyopathy, peripheral nerve injury, spinal injury, amyotrophic lateral sclerosis, multiple sclerosis, cerebral ischemic diseases, senile dementia of Alzheimer's type, Parkinson's disease or Huntington's chorea, depression, inflammatory bowel disease, chronic pain, behavioral abnormalities accompanied by dementia, anxiety, paresthesia or pain caused by a wound, diabetes, impaired glucose tolerance, hyperlipidemia, hyperinsulinemia, obesity, hyperphagia, hypertension, and cardiovascular diseases. I can also be used as ameliorating agents for peripheral neuropathies or cerebral metabolic disorders. The neurotrophin production/secretion promoting activity of 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl] oxazole is presented. Although the methods of preparation are not claimed, >120 example prepns. are included.

IT 327188-30-7P, Ethyl 2-chloro-4-(5-chloro-2-thienyl)-5-oxazolebutanoate 327189-22-0P, Ethyl 4-[4-(5-chloro-2-thienyl)-2-oxo-4-oxazolin-5-yl]butanoate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazoles and thiazoles useful as neurotrophin production/secretion promoting agents)

RN 327188-30-7 CAPLUS
CN 5-Oxazolebutanoic acid, 2-chloro-4-(5-chloro-2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 327189-22-0 CAPLUS
CN 5-Oxazolebutanoic acid, 4-(5-chloro-2-thienyl)-2,3-dihydro-2-oxo-, ethyl ester (CA INDEX NAME)



L23 ANSWER 17 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:115148 CAPLUS Full-text
DOCUMENT NUMBER: 134:178571
TITLE: Preparation of 6-azauracil derivatives as

interleukin-5 inhibitors

INVENTOR(S): Lacrampe, Jean Fernand Armand; Freyne, Eddy Jean Edgard; Deroose, Frederik Dirk; Fortin, Jerome Michel Claude; Coesemans, Erwin

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2001010866	A1	20010215	WO 2000-EP7358		20000731	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
CA 2380759	A1	20010215	CA 2000-2380759		20000731	<--
BR 2000013014	A	20020416	BR 2000-13014		20000731	<--
EP 1206471	A1	20020522	EP 2000-948015		20000731	<--
EP 1206471	B1	20060301				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL						
TR 200200310	T2	20020821	TR 2002-310		20000731	<--
HU 2002002692	A2	20021228	HU 2002-2692		20000731	<--
HU 2002002692	A3	20030128				
JP 2003506451	T	20030218	JP 2001-515675		20000731	<--
EE 200200057	A	20030415	EE 2002-57		20000731	<--
NZ 516506	A	20040227	NZ 2000-516506		20000731	<--
AU 780047	B2	20050224	AU 2000-61609		20000731	<--
AT 318811	T	20060315	AT 2000-948015		20000731	<--
ES 2260031	T3	20061101	ES 2000-948015		20000731	<--
TW 271404	B	20070121	TW 2000-89115824		20000804	<--
KR 795484	B1	20080116	KR 2002-700704		20020117	<--
BG 106367	A	20020930	BG 2002-106367		20020130	<--
IN 2002MN00144	A	20050318	IN 2002-MN144		20020131	<--
NO 2002000565	A	20020326	NO 2002-565		20020205	<--
NO 322386	B1	20060925				
ZA 2002001007	A	20030505	ZA 2002-1007		20020205	<--
MX 2002PA01343	A	20020722	MX 2002-PA1343		20020206	<--
US 20030114453	A1	20030619	US 2002-75876		20020214	<--
US 6911444	B2	20050628				
HK 1048634	A1	20050930	HK 2003-100718		20030128	<--
PRIORITY APPLN. INFO.:			EP 1999-870170	A	19990806	<--
			EP 1999-126035	A	19991227	<--
			WO 2000-EP7358	W	20000731	<--

OTHER SOURCE(S): MARPAT 134:178571

GI



I



II

AB The title compds. (I) [p = 0-4; X = O, S, NR5, or a direct bond; or XR2 taken together = CN; R1 = independently C(O)ZR14, (un)substituted alkyl, halo, OH, SH, alkoxy, alkylthio, alkylcarbonyloxy, aryl, CN, NO2, hetercyclyl, R6, or NR7R8; R2 = heterocyclyl, (un)substituted cycloalkyl, alkoxy, or alkylthio, heterocyclyl(oxy), heterocyclylthio, etc.; R3 and R4 = independently H or (cyclo)alkyl; or R3 and R4 taken together form an alkenediyl; R5 = H or alkyl; R6 = (un)substituted (cyclo)alkylsulfonyl, amino(alkyl)sulfonyl, heterocyclylsulfonyl, etc.; R7 and R8 = independently H, (cyclo)alkyl, (di)hydroxyalkyl, mercaptoalkyl, aryl(alkyl), alkyloxyalkyl, alkyl(thio)carbonyl, aryl(thio)carbonyl, heterocyclyl(thio)carbonyl, C(O)ZR14, or (un)substituted aminocarbonyl, etc.; or R7 and R8 together with the N to which they are attached form a pyrrolinone, piperidinone, or hexahydroazepinone; R14 = H, alkynyl, or (un)substituted (alkyl)acyl, alkyl, alkenyl, heterocyclyl, etc.; Z = O, S, NH, CH2O, or CH2S; or ZR14 taken together = CH2CN or CH2PO3H2 and its esters] and their N-oxides, pharmaceutically acceptable salts, or stereochem. isomers were prepared as selective chemokine inhibitors. For example, 2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)- α,α-dimethylbenzeneethanethioamide was coupled with Et β-bromo-γ-oxobenzenebutanoate (46.5%), cyclized to form the thiazoleacetic acid (79%), and esterified with 3-bromodihydro-2(3H)-furanone to give II. As selective interleukin 5 (IL-5) and monocyte chemotactic protein-1 and -3 (MCP-1 and MCP-3) inhibitors, I are useful for treating eosinophil-dependent inflammatory diseases, especially bronchial asthma (no data). Processes using I for marking receptors and imaging organs via radiolabeling are also claimed.

IT 325968-66-9P 325968-67-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of IL-5 inhibiting thiazolylalkylphenyl -6-azauracil derivs. by coupling of 4-dioxotriazinyl-α,α-dimethylbenzeneethanethioamides with α-oxoalkyl halides, cyclization, and addition of functionally substituted groups)

RN 325968-66-9 CAPLUS

CN 5-Thiazoleacetic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 325968-67-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 18 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:29404 CAPLUS Full-text
DOCUMENT NUMBER: 136:340636
TITLE: Synthesis of 5-(hetero)aryl-1,3,4-oxadiazolyl -2-acetic acids
AUTHOR(S): Janda, Lubomir
CORPORATE SOURCE: Aldrich Chemical Co., Inc., Milwaukee, WI, 53233, USA
SOURCE: Heterocyclic Communications (2001), 7(5), 411-416
CODEN: HCOMEX; ISSN: 0793-0283
PUBLISHER: Freund Publishing House Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:340636
GI



I

AB Et (1H-tetrazol-5-yl)acetate is acylated with aroyl chlorides and heteroaroyl chlorides in pyridine. The intermediate acyltetrazoles undergo thermal degradation to Et [5-(hetero)aryl-1,3,4-oxadiazol -2-yl]acetates [I; Ar = 2-furanyl, 2-thienyl, (un)substituted phenyl]. The corresponding acetic acids are obtained by potassium hydroxide mediated hydrolysis of the esters in anhydrous ethanol.

IT 415679-22-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and conversion to carboxylic acid)
RN 415679-22-0 CAPLUS
CN 1,3,4-Oxadiazole-2-acetic acid, 5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



IT 415679-28-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 415679-28-6 CAPLUS
CN 1,3,4-Oxadiazole-2-acetic acid, 5-(2-thienyl)- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 19 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:87730 CAPLUS Full-text
DOCUMENT NUMBER: 128:154084
TITLE: Preparation of aralkylazoles as tyrosine kinase inhibitors useful as antitumor agents.
INVENTOR(S): Momose, Yu; Matsutani, Etsuya
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803505	A2	19980129	WO 1997-JP2479	19970717 <--
WO 9803505	A3	19980625		

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2260999	A1	19980129	CA 1997-2260999	19970717	<--
CA 2260999	C	20060711			
AU 9734616	A	19980210	AU 1997-34616	19970717	<--
EP 912562	A1	19990506	EP 1997-930819	19970717	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
CN 1223653	A	19990721	CN 1997-195822	19970717	<--
CN 1077107	B	20020102			
EP 1270571	A1	20030102	EP 2002-79001	19970717	<--
EP 1270571	B1	20060906			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
AT 338754	T	20060915	AT 2002-79001	19970717	<--
ZA 9706378	A	19990119	ZA 1997-6378	19970718	<--
JP 11060571	A	19990302	JP 1997-193709	19970718	<--
JP 4056589	B2	20080305			
US 6211215	B1	20010403	US 1998-180955	19981118	<--
CN 1349990	A	20020522	CN 2001-119519	20010518	<--
PRIORITY APPLN. INFO.:			JP 1996-191100	A 19960719	<--
			JP 1997-155177	A 19970612	<--
			EP 1997-930819	A3 19970717	<--
			WO 1997-JP2479	W 19970717	<--

OTHER SOURCE(S): MARPAT 128:154084

GI



I

AB Title compds. [I; R = (substituted) heteroaryl; X = O, (oxidized) S, CO, CH(OH); Y = CH, N; m = 0-10; n = 1-5; NB = (substituted) aromatic azolyl; ring containing Y is optionally further substituted], were prepared Thus, 3-[4-[2-[(E)-phenylethenyl]-4-oxazolylmethoxy]phenyl]propyl methanesulfonate (preparation given) was added to a mixture of imidazole and NaH in DMF followed by stirring for 1.5 h at 70° to give 4-[4-[3-(1-imidazolyl)propyl]phenoxymethyl]-2-[(E)-2-phenylethenyl] oxazole. The latter inhibited proliferation of MDA-MB-453 human breast cancer cells with IC50 = 0.25 nM.

IT 202595-22-0P 202595-23-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aralkylazoles as tyrosine kinase inhibitors useful as antitumor agents)

RN 202595-22-0 CAPLUS

CN 4-Oxazoleacetic acid, 2-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 202595-23-1 CAPLUS
CN 4-Oxazolepropanoic acid, 2-(2-thienyl)-, ethyl ester (CA INDEX NAME)



L23 ANSWER 20 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:55635 CAPLUS Full-text
DOCUMENT NUMBER: 128:114954
TITLE: Preparation and formulation of thienyloxadiazole derivatives and analogs as anti-phencyclidine agents
INVENTOR(S): Kimura, Takenori; Murakami, Takeshi; Ohmori, Junya; Morita, Takuma; Tsukamoto, Shin-ichi
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9800420	A1	19980108	WO 1997-JP2255	19970630 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 414795	B	20001211	TW 1997-86109077	19970628 <--
CA 2260263	A1	19980108	CA 1997-2260263	19970630 <--
AU 9732767	A	19980121	AU 1997-32767	19970630 <--
AU 714701	B2	20000106		
EP 921123	A1	19990609	EP 1997-928516	19970630 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1223648	A	19990721	CN 1997-195963	19970630 <--
BR 9709947	A	19990810	BR 1997-9947	19970630 <--
RU 2172737	C2	20010827	RU 1999-101864	19970630 <--
JP 3218045	B2	20011015	JP 1998-503989	19970630 <--
KR 2000022061	A	20000425	KR 1998-710464	19981221 <--
US 6090804	A	20000718	US 1998-214228	19981230 <--
MX 9900258	A	20000531	MX 1999-258	19990104 <--

PRIORITY APPLN. INFO.: JP 1996-170970 A 19960701 <--
WO 1997-JP2255 W 19970630 <--
OTHER SOURCE(S): MARPAT 128:114954
GI



I



II

AB The title compds. I [R1 is A1X1R3; R2 is A2X2R4 or nil; B is a four- to ten-membered nitrogenous cycloalkyl or a five- or six-membered nitrogenous unsatd. heterocycle; Ar is aryl or heteroaryl; A1, A2 and A3 are each independently a bond or lower alkylene; X1 and X2 are each independently a bond, O, S or the like; and R3 and R4 are each independently hydrogen, cyclic imido, lower alkyl, cycloalkyl, aryl or aralkyl, with the provisos that when Ar is a thiazole ring, at least either of A1 and A2 is lower alkylene and that when Ar is a benzene ring, compds. wherein one of R1 and R2 is Me or halogeno and the other thereof is hydrogen are excluded], useful as psychotropics and antischizophrenic agents, are prepared The title compound II at 10 mg/kg s.c. gave statistically significant inhibition of phencyclidine-induced locomotor stimulation in rats.

IT 201546-17-0P 201546-18-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienyloxadiazole derivs. and analogs as anti-phencyclidine agents)

RN 201546-17-0 CAPLUS

CN 1,2,4-Oxadiazole-5-acetic acid, 3-[5-[(hexahydro-1H-azepin-1-yl)methyl]-2-thienyl]-, ethyl ester (CA INDEX NAME)



RN 201546-18-1 CAPLUS
CN 1,2,4-Oxadiazole-5-acetic acid, 3-[5-[(hexahydro-1H-azepin-1-yl)methyl]-2-thienyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 21 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:713389 CAPLUS Full-text
DOCUMENT NUMBER: 130:104774
TITLE: N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 2. Structure-Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety
AUTHOR(S): Collins, Jon L.; Blanchard, Steven G.; Boswell, G. Evan; Charifson, Paul S.; Cobb, Jeff E.; Henke, Brad R.; Hull-Ryde, Emily A.; Kazmierski, Wieslaw M.; Lake, Debra H.; Leesnitzer, Lisa M.; Lehmann, Juergen; Lenhard, James M.; Orband-Miller, Lisa A.; Gray-Nunez, Yolanda; Parks, Derek J.; Plunkett, Kelli D.; Tong, Wei-Qin
CORPORATE SOURCE: Glaxo Wellcome Research and Development, Research Triangle Park, NC, 27709, USA
SOURCE: Journal of Medicinal Chemistry (1998), 41(25), 5037-5054
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We previously reported the identification of (2S)-((2-benzoylphenyl)amino)- 3-{4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl}propanoic acid (I) (PPARγ pKi = 8.94, PPARγ pEC50 = 9.47) as a potent and selective PPARγ agonist. We now report the expanded structure-activity relationship around the Ph alkyl ether moiety by pursuing both a classical medicinal chemical approach and a solid-phase chemical approach for analog synthesis. The solution-phase strategy focused on evaluating the effects of oxazole and Ph ring replacements of the 2-(5-methyl-2-phenyloxazol-4-yl)ethyl side chain of I with several replacements providing potent and selective PPARγ agonists with improved aqueous solubility Specifically, replacement of the Ph ring of the phenyloxazole moiety with a 4-pyridyl group to give (2S)-((2-benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-pyridin-4-yloxazol-4-

yl)ethoxy]phenyl}propionic acid (PPARγ pKi = 8.85, PPARγ pEC50 = 8.74) or a 4-methylpiperazine to give (2S)-((2-benzoylphenyl)amino)-3-(4- {2-[5-methyl-2-(4-methylpiperazin-1-yl)thiazol -4-yl]ethoxy}phenyl)propionic acid (PPARγ pKi = 8.66, PPARγ pEC50 = 8.89) provided two potent and selective PPARγ agonists with increased solubility in pH 7.4 phosphate buffer and simulated gastric fluid as compared to I. The second strategy took advantage of the speed and ease of parallel solid-phase analog synthesis to generate a more diverse set of Ph alkyl ethers which led to the identification of a number of novel, high-affinity PPARγ ligands (PPARγ pKi's 6.98-8.03). The combined structure-activity data derived from the two strategies provide valuable insight on the requirements for PPARγ binding, functional activity, selectivity, and aqueous solubility

IT 196810-94-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, optimization and SAR of N-(2-benzoylphenyl)-L-tyrosine analogs
as PPARγ agonists)

RN 196810-94-3 CAPLUS
CN 4-Oxazoleacetic acid, 5-methyl-2-(5-methyl-2-thienyl)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 22 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:594721 CAPLUS Full-text
DOCUMENT NUMBER: 127:278064
TITLE: Substituted 4-hydroxyphenylalkanoic acid derivatives with agonist activity to PPAR-gamma
INVENTOR(S): Willson, Timothy Mark; Mook, Robert Anthony, Jr.; Kaldor, Istvan; Henke, Brad Richard; Deaton, David Norman; Collins, Jon Loren; Cobb, Jeffrey Edmond; et al.
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9731907	A1	19970904	WO 1997-EP916	19970226 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,

VN, YU
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2247443	A1	19970904	CA 1997-2247443		19970226 <--
AU 9720935	A	19970916	AU 1997-20935		19970226 <--
AU 717699	B2	20000330			
ZA 9701645	A	19971210	ZA 1997-1645		19970226 <--
EP 888317	A1	19990107	EP 1997-906130		19970226 <--
EP 888317	B1	20010912			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI					
CN 1218460	A	19990602	CN 1997-193988		19970226 <--
CN 1093124	B	20021023			
BR 9707786	A	19990727	BR 1997-7786		19970226 <--
JP 2000507216	T	20000613	JP 1997-530586		19970226 <--
JP 3255930	B2	20020212			
NZ 331381	A	20000623	NZ 1997-331381		19970226 <--
HU 2000004845	A2	20010528	HU 2000-4845		19970226 <--
HU 2000004845	A3	20010730			
IL 125796	A	20010614	IL 1997-125796		19970226 <--
AT 205485	T	20010915	AT 1997-906130		19970226 <--
ES 2163125	T3	20020116	ES 1997-906130		19970226 <--
PT 888317	T	20020328	PT 1997-906130		19970226 <--
SK 282753	B6	20021203	SK 1998-1163		19970226 <--
HR 970110	B1	20030630	HR 1997-110		19970226 <--
IN 1997DE00491	A	20050311	IN 1997-DE491		19970226 <--
CZ 295383	B6	20050713	CZ 1998-2750		19970226 <--
PL 191118	B1	20060331	PL 1997-328871		19970226 <--
TW 391958	B	20000601	TW 1997-86102826		19970307 <--
US 6294580	B1	20010925	US 1998-125750		19980825 <--
NO 9803940	A	19981027	NO 1998-3940		19980827 <--
NO 311516	B1	20011203			
HK 1015369	A1	20020215	HK 1999-100498		19990205 <--
PRIORITY APPLN. INFO.:			GB 1996-4242	A	19960228 <--
			WO 1997-EP916	W	19970226 <--

OTHER SOURCE(S): MARPAT 127:278064

AB Compds. 4-(A-B-O)C6H4-Q-CHZCO2R1 [A = (un)substituted Ph, heterocyclyl, fused bicyclic ring; B = alkylene, heterocyclyl; Q = alkylene; R1 = H, alkyl; Z = alkylenephenyl, NR3R4 (R3 = H, alkyl; R4 = YXOTR5, YCH(OH)TR5 with Y = bond, alkylene, alkenylene, cycloalkylene, etc. and T = bond, O, etc. and R5 = alkyl, cycloalkyl, (un)substituted Ph)] were prepared and their agonist activity to PPAR-gamma determined E.g., O-benzyl L-tyrosine, dicyclohexylamine, and 1-benzoylacetone were refluxed in MeOH to give 3-(4-benzyloxyphenyl)-2(S)-(1-methyl-3-oxo-3-phenylpropenylamino)propionic acid dicyclohexylamine salt.

IT 196809-83-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (hydroxyphenyl)alkanoic acids with agonist activity to PPAR-gamma)

RN 196809-83-3 CAPLUS

CN 4-Oxazoleacetic acid, 5-methyl-2-(3-methyl-2-thienyl)-, methyl ester (CA INDEX NAME)



IT 196810-94-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (hydroxyphenyl)alkanoic acids with agonist activity to PPAR-gamma)
RN 196810-94-3 CAPLUS
CN 4-Oxazoleacetic acid, 5-methyl-2-(5-methyl-2-thienyl)-, methyl ester (CA INDEX NAME)



L23 ANSWER 23 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:221624 CAPLUS Full-text
DOCUMENT NUMBER: 108:221624
ORIGINAL REFERENCE NO.: 108:36383a,36386a
TITLE: Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds
AUTHOR(S): Moriya, Tamon; Seki, Masahiko; Takabe, Seiichi; Matsumoto, Kazuo; Takashima, Kohki; Mori, Tetsuji; Odawara, Akio; Takeyama, Shigeyuki
CORPORATE SOURCE: Res. Lab. Appl. Biochem., Tanabe Seiyaku Co., Ltd., Osaka, 532, Japan
SOURCE: Journal of Medicinal Chemistry (1988), 31(6), 1197-204
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:221624
GI



I II

AB Derivs. of 5-furyl-4-oxazoleacetic acid I [R = (un)substituted 2-furyl, 3-furyl, 3-thienyl, pyrrolidino; R1 = (un)substituted Ph, Me, CHMe2, cyclohexyl; R2 = H, Me, Et; R3 = H, Me; R4 = H, Et, Bu, heptyl, nicotinyl] (50 compds.) were synthesized and evaluated for their hypolipemic activities in rats. On the basis of the structure-activity relationships and subacute toxicities, ester II was selected as a candidate compound for development. II reduced serum cholesterol and triglyceride levels by 23% and 35%, resp., at 0.05% in the diet in normal rats, and it was about 10 times more active in hereditary hyperlipemic rats than in normal rats. II inhibited platelet aggregation in vitro and also normalized hyperaggregability of hyperlipidemic plasma platelets ex vivo.

IT 105770-44-3P 113598-16-6P 113598-17-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antilipemic and platelet aggregation-inhibiting activity of)

RN 105770-44-3 CAPLUS
CN 4-Thiazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 113598-16-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(1-methylethyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 113598-17-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-heptyl-5-(3-thienyl)- (CA INDEX NAME)



IT 113598-13-3P 113598-14-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, saponification, and antilipemic and platelet aggregation-inhibiting
activity of)
RN 113598-13-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(1-methylethyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 113598-14-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-heptyl-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



L23 ANSWER 24 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:6027 CAPLUS Full-text
DOCUMENT NUMBER: 108:6027
ORIGINAL REFERENCE NO.: 108:1147a,1150a
TITLE: Preparation of alkyl 5-substituted-3-mercapto-4H-1,2,4-triazol-4-yl acetates as antiinflammatories and antibiotic intermediates
INVENTOR(S): Veverka, Miroslav; Marchalin, Miroslav
PATENT ASSIGNEE(S): Czech.
SOURCE: Czech., 5 pp.
CODEN: CZXXA9
DOCUMENT TYPE: Patent
LANGUAGE: Slovak
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 234892	B1	19850416	CS 1984-882	19840207 <--
PRIORITY APPLN. INFO.:			CS 1984-882	19840207 <--

OTHER SOURCE(S): CASREACT 108:6027

GI



I

AB The title compds. [I; R = H, C1-6 alkyl, C3-6 cycloalkyl, cyanomethyl, carbamoyl, -CH2CO2R3, -CO2R4; R1 = H alkali metal, alkaline earth metal, ammonium, cyanomethyl, C1-4 alkyl, -CH2CO2R5; R2, R3 = C1-4 alkyl; R4 = alkyl, benzyl, (substituted) Ph; R5 = C1-4 alkyl, benzhydryl, H, alkali metal, alkaline earth metal, ammonium] are prepared by cyclization of thiosemicarbazides in an alkaline medium and S-alkylation. I are useful as intermediates for semisynthetic antibiotics and nonsteroidal antiinflammatories (no data). A solution of 10g 1(2-furoyl)-4-carbethoxymethyl-3-thiosemicarbazide in 450 mL EtOH in the presence of 0.9 g Na was refluxed for 12 h to give 7.3 g Et 5-(2-furyl)-3-mercaptor-4H- 1,2,4-triazol-4-yl acetate.

IT 110167-62-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and alkylation of)

RN 110167-62-9 CAPLUS

CN 4H-1,2,4-Triazole-4-acetic acid, 1,5-dihydro-3-(2-thienyl)-5-thioxo-, ethyl ester (CA INDEX NAME)





L23 ANSWER 25 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:515537 CAPLUS Full-text

DOCUMENT NUMBER: 107:115537

ORIGINAL REFERENCE NO.: 107:18727a,18730a

TITLE: Addition-cyclization reactions of ethyl isothiocyanatoacetate with carboxylic acid hydrazides

AUTHOR(S): Veverka, Miroslav; Marchalin, Miroslav

CORPORATE SOURCE: Drug Res. Inst., Bratislava, 811 04, Czech.

SOURCE: Collection of Czechoslovak Chemical Communications (1987), 52(1), 113-19
CODEN: CCCCAK; ISSN: 0366-547X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 107:115537

GI



I



II

AB Et (3-substituted 5-thioxo-1,2,4-triazolin-4-yl)acetates I (R = e.g. H, Me, Ph, PhCH2, 2-thienyl) were prepared by addition-cyclization reaction of Et isothiocyanatoacetate with carboxylic acid hydrazides in the presence of NaOEt. Thermal cyclization of the adduct AcNHNHCSNHCH2CO2Et in DMF afforded 1-acetamido-2-thiohydantoin II. The effect of substituents on the cyclization course and the thione-thiol tautomerism are discussed.

IT 110167-62-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 110167-62-9 CAPLUS

CN 4H-1,2,4-Triazole-4-acetic acid, 1,5-dihydro-3-(2-thienyl)-5-thioxo-, ethyl ester (CA INDEX NAME)





L23 ANSWER 26 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:18570 CAPLUS Full-text

DOCUMENT NUMBER: 106:18570

ORIGINAL REFERENCE NO.: 106:3189a,3192a

TITLE: Tetrazole derivatives

INVENTOR(S): Matsumoto, Kazuo; Moriya, Tamon; Takashima, Koki

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61167685	A	19860729	JP 1985-9678	19850121 <--
JP 04049548	B	19920811		

PRIORITY APPLN. INFO.: JP 1985-9678 19850121 <--

GI



AB The title compds. [I; R = Q; R1 = (hetero)aryl, (cyclo)alkyl; X1 = S, O; X = halo], useful as anticholesteremics, were prepared Thus, a mixture of I (R = cyano; R1 = 2-furyl; X1 = S; X = Cl), NaN3 and NH4Cl in DMF was heated at 100-110° for 10 h to give 58% I (R = Q; R1 = 2-furyl; X1 = S; X = Cl). Rats fed with a diet containing I showed a 37 and 76% decrease in serum cholesterol and triglycerides, resp.

IT 105770-44-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as anticholesteremic)

RN 105770-44-3 CAPLUS

CN 4-Thiazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



L23 ANSWER 27 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:33032 CAPLUS Full-text

DOCUMENT NUMBER: 106:33032

ORIGINAL REFERENCE NO.: 106:5543a,5546a

TITLE: Thiazole and oxazole derivatives

INVENTOR(S): Matsumoto, Kazuo; Moriya, Tamon; Takashima, Koki

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61167676	A	19860729	JP 1985-9677	19850121 <--

PRIORITY APPLN. INFO.: JP 1985-9677 19850121 <--

GI



I

AB The title compds. [I; R1 = (hetero)aryl, (cyclo)alkyl; R2 = CONH2, cyano, C(S)NH2, CO2R3; R3 = H, alkyl; X = halo; X1 = O, S], useful as anticholesteremics (no data), were prepared Thus, a mixture of R1COCH(NHCOC6H4Cl-p)CH2CO2Et (R1 = 2-furyl) and 2,4-bis(methylthio)- 1,3,2,4-dithiadiphosphetane 2,4-disulfide in THF was heated at 40° for 1 h to give 91% I(R1 = 2-furyl; R2 = CO2Et).

IT 105584-37-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as anticholesteremic)

RN 105584-37-0 CAPLUS

CN 4-Thiazoleacetic acid, 2-(4-chlorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



L23 ANSWER 28 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:129826 CAPLUS Full-text

DOCUMENT NUMBER: 104:129826

ORIGINAL REFERENCE NO.: 104:20541a,20544a

TITLE: Synthesis of amino acids and related compounds. 29. Synthesis and hypolipidemic activities of 5-thienyl-4-oxazoleacetic acid derivatives

AUTHOR(S): Moriya, Tamon; Takabe, Seiichi; Maeda, Sadao; Matsumoto, Kazuo

CORPORATE SOURCE: Res. Lab. Appl. Biochem., Tanabe Seiyaku Co., Ltd., Osaka, 532, Japan

SOURCE: Journal of Medicinal Chemistry (1986), 29(3), 333-41
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 104:129826

GI



I

AB A series of 2,5-disubstituted 4-oxazoleacetic acid derivs. was synthesized and evaluated for hypolipidemic activity. Among them, those with a thienyl group at C-5 of the oxazole ring exerted highly potent hypolipidemic effects in rats. Thienyloxazoleacetic acid I was the most potent derivative, being about 2 times as active as clofibrate in normal SD male rats. I had an improved antiarterioschlerosis index and showed inhibition of platelet aggregation ex vivo.

IT 99923-96-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(hypolipidemic activity of)

RN 99923-96-3 CAPLUS

CN 4-Oxazolepropanoic acid, 2-(4-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



IT 85162-07-8P 85162-12-5P 85162-17-0P
85162-19-2P 85162-20-5P 85162-21-6P
85162-22-7P 85162-23-8P 85162-24-9P
85162-25-0P 85162-28-3P 85162-29-4P
90430-15-2P 99923-76-9P 99923-83-8P
99923-84-9P 99923-85-0P 99923-86-1P
99923-87-2P 99924-07-9P 99924-08-0P
99924-09-1P 99924-10-4P 99946-60-8P
99946-61-9P 99946-62-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and hypolipidemic activity of)

RN 85162-07-8 CAPLUS

CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, methyl ester (CA INDEX NAME)



RN 85162-12-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)- (CA INDEX NAME)



RN 85162-17-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



RN 85162-19-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-20-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



RN 85162-21-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-22-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-23-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



RN 85162-24-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-25-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-28-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-29-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 90430-15-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(2-thienyl)- (CA INDEX NAME)



RN 99923-76-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-bromophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 99923-83-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(4-fluorophenyl)-2-(3-thienyl)- (CA INDEX NAME)



RN 99923-84-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(2-thienyl)- (CA INDEX NAME)



RN 99923-85-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(5-methyl-2-thienyl)- (CA INDEX NAME)



RN 99923-86-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methylphenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 99923-87-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methoxyphenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 99924-07-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 99924-08-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, 3-pyridinylmethyl ester (CA INDEX NAME)



RN 99924-09-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, octyl ester (CA INDEX NAME)



RN 99924-10-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, dodecyl ester (CA INDEX NAME)



RN 99946-60-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3,4-dichlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 99946-61-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, octadecyl ester (CA INDEX NAME)



RN 99946-62-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, 2,3-dihydroxypropyl ester (CA INDEX NAME)



IT 85162-05-6P 85162-06-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification and hypolipidemic activity of)
RN 85162-05-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-06-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



IT 99923-77-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 99923-77-0 CAPLUS
CN 4-Oxazoleacetic acid, 5-(5-bromo-2-thienyl)-2-(4-chlorophenyl)-, ethyl ester (CA INDEX NAME)



IT 85162-04-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, borohydride reduction, saponification, and hypolipidemic activity of)
RN 85162-04-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



IT 85162-11-4P 85162-13-6P 85162-14-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, esterification, and hypolipidemic activity of)
RN 85162-11-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-13-6 CAPLUS

CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-14-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



IT 99923-94-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, saponification, and hypolipidemic acitvity of)
RN 99923-94-1 CAPLUS
CN 4-Oxazolepropanoic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



IT 85162-08-9P 85162-09-0P 85162-10-3P
85162-26-1P 85162-27-2P 99923-75-8P
99923-78-1P 99923-79-2P 99923-80-5P
99946-59-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, saponification, and hypolipidemic activity of)
RN 85162-08-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-09-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-10-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-26-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-27-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 99923-75-8 CAPLUS
CN 4-Oxazoleacetic acid, 5-(4-fluorophenyl)-2-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 99923-78-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methylphenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 99923-79-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-methoxyphenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 99923-80-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3,4-dichlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 99946-59-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(5-methyl-2-thienyl)-, ethyl ester (CA INDEX NAME)



L23 ANSWER 29 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:400692 CAPLUS Full-text
DOCUMENT NUMBER: 101:692
ORIGINAL REFERENCE NO.: 101:119a,122a
TITLE: Thienyloxazolylacetate derivatives as anticholesteremics
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59036614	A	19840228	JP 1982-147970	19820825 <--

PRIORITY APPLN. INFO.: JP 1982-147970 19820825 <--
GI



I

AB Thienyloxazolylacetates (I, R = H or halo; R1 = H or alkyl) are anticholesteremics. Thus, Et 2-[2-(4-fluorophenyl)-5-(3-thienyl)-4-oxazolyl]acetate (II) [85162-04-5] was prepared by ring closure of Et 3-(4-fluorobenzoylamino)-3-(3-thienylcarbonyl)propionate [85162-38-5]. A diet containing 0.05% II given to rats decreased serum cholesterol and triglycerides 19 and 31%, resp., in 1 wk.

IT 85162-04-5P 85162-05-6P 85162-06-7P
85162-07-8P 85162-08-9P 85162-09-0P
85162-10-3P 85162-11-4P 85162-12-5P
85162-13-6DP, derivs. 85162-13-6P 85162-15-8P
85162-16-9P 85162-17-0P 85162-18-1P
85162-19-2P 85162-20-5P 85162-21-6P
85162-22-7P 85162-23-8P 85162-24-9P
85162-25-0P 85162-26-1P 85162-27-2P
85162-28-3P 85162-29-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and anticholesteremic activity of)

RN 85162-04-5 CAPLUS

CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-05-6 CAPLUS

CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-06-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-07-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, methyl ester (CA INDEX NAME)



RN 85162-08-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-09-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-10-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-11-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-12-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)- (CA INDEX NAME)



RN 85162-13-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-13-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-15-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 85162-16-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, potassium salt (9CI) (CA INDEX NAME)



RN 85162-17-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, pentyl ester (CA

INDEX NAME)



RN 85162-18-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-19-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-20-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



RN 85162-21-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-22-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-23-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



RN 85162-24-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-25-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-26-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-27-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-28-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-29-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



L23 ANSWER 30 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:160701 CAPLUS Full-text
DOCUMENT NUMBER: 98:160701
ORIGINAL REFERENCE NO.: 98:24391a,24394a
TITLE: 4-Chlorothienyl-4-thiazolealkanecarboxylic acid derivatives and pharmaceutical preparations containing them
INVENTOR(S): Uhlendorf, Joachim; Graf, Erich
PATENT ASSIGNEE(S): Nattermann, A., und Cie. G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3128492	A1	19830203	DE 1981-3128492	19810718 <--
PRIORITY APPLN. INFO.:			DE 1981-3128492	19810718 <--

OTHER SOURCE(S): MARPAT 98:160701
GI



I

AB The antithrombotic (no data) title compds. I [R = H, alkali metal, C1-6 hydrocarbon; R1 = (un)substituted phenylalkyl, (un)substituted phenylthioalkyl, (un)substituted Ph, X = C1-3 alkylene] were prepared Thus, 7.6 g PhCH2CSNH2 was treated with 14.9 g 3-(5-chloro-2-thenoyl)-3-bromopropanoic acid in DMF at 60-70° to give 7.3 g I (R = H, R1 = PhCH2, X = CH2).

IT 85346-86-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and esterification of)

RN 85346-86-7 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(phenylmethyl)- (CA INDEX NAME)



IT 85346-87-8P 85346-88-9P 85346-90-3P
85346-91-4P 85346-92-5P 85346-93-6P
85346-94-7P 85346-95-8P 85346-96-9P
85346-97-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 85346-87-8 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(phenylmethyl)-, ethyl ester (CA INDEX NAME)



RN 85346-88-9 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(2-hydroxyphenyl)-, monosodium salt (9CI) (CA INDEX NAME)



RN 85346-90-3 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(phenylmethyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 85346-91-4 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(phenylmethyl)-, methyl ester (CA INDEX NAME)



RN 85346-92-5 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[[(4-methylphenyl)thio]methyl]- (CA INDEX NAME)



RN 85346-93-6 CAPLUS
CN 5-Thiazoleacetic acid, 2-[[(4-chlorophenyl)thio]methyl]-4-(5-chloro-2-thienyl)- (CA INDEX NAME)



RN 85346-94-7 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-(2-phenylethenyl)- (CA INDEX NAME)



RN 85346-95-8 CAPLUS
CN 5-Thiazoleacetic acid, 4-(5-chloro-2-thienyl)-2-[2-(2-propenylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 85346-96-9 CAPLUS
CN 5-Thiazolepropanoic acid, 4-(5-chloro-2-thienyl)-2-[2-(2-propenylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 85346-97-0 CAPLUS
CN 5-Thiazolebutanoic acid, 4-(5-chloro-2-thienyl)-2-[2-(2-propenylthio)phenyl]- (9CI) (CA INDEX NAME)



L23 ANSWER 31 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:198197 CAPLUS Full-text
DOCUMENT NUMBER: 98:198197
ORIGINAL REFERENCE NO.: 98:30131a,30134a
TITLE: Thienyloxazolylacetic acid derivatives
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57188587	A	19821119	JP 1981-73777	19810515 <--
JP 62056152	B	19871124		
US 4460596	A	19840717	US 1982-372990	19820429 <--
PRIORITY APPLN. INFO.:			JP 1981-73777 A	19810515 <--

OTHER SOURCE(S): CASREACT 98:198197; MARPAT 98:198197
GI



I



II

AB Twenty-six title derivs. I (R = H, halo; R1 = H, alkyl) were prepared by dehydration cyclization of II (R2 = alkyl) optionally followed by hydrolysis. Hypolipemic and platelet aggregation inhibitory data of I were shown in rats in comparison with clofibrate. Thus, 24.6 g POCl3 was added to 40 g Et 3-(4-fluorobenzoylamino)-3-(3-thienylcarbonyl)propionate in DMF at 0-5° and the mixture stirred 4 h at 0-5° and overnight at room temperature to give 85.5% I (R = 4-F, R1 = Et, 3-thienyl).

IT 85162-09-0P 85162-17-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and hypolipemic activity of)

RN 85162-09-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-17-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



IT 85162-04-5P 85162-08-9P 85162-11-4P
85162-12-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activity of)

RN 85162-04-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-08-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-11-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-12-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)- (CA INDEX NAME)



IT 85162-13-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and platelet aggregation inhibitor activity of)
RN 85162-13-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)- (CA INDEX NAME)



IT 85162-05-6P 85162-06-7P 85162-07-8P
85162-10-3P 85162-14-7P 85162-15-8P
85162-16-9P 85162-18-1P 85162-19-2P
85162-20-5P 85162-21-6P 85162-22-7P
85162-23-8P 85162-24-9P 85162-25-0P
85162-26-1P 85162-27-2P 85162-28-3P
85162-29-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 85162-05-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-06-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-07-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, methyl ester (CA INDEX NAME)



RN 85162-10-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-14-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-15-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 85162-16-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, potassium salt (9CI) (CA INDEX NAME)



RN 85162-18-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-19-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-20-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



RN 85162-21-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-22-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-23-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



RN 85162-24-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-25-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-26-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-27-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-28-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-29-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



L23 ANSWER 32 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:143400 CAPLUS Full-text
DOCUMENT NUMBER: 98:143400
ORIGINAL REFERENCE NO.: 98:21849a,21852a
TITLE: Thienyloxazolylacetic acid derivatives
INVENTOR(S): Matsumoto, Kazuo; Takashima, Kohki
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd. , Japan
SOURCE: Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 65145	A1	19821124	EP 1982-103636	19820428 <--
EP 65145	B1	19841003		
R: CH, DE, FR, GB				
PRIORITY APPLN. INFO.:			JP 1981-73771 A	19810515 <--

OTHER SOURCE(S): MARPAT 98:143400
GI



I

AB The title compds. I [R = CH2CO2R3; R1 = Ph, halophenyl; R2 = 2-, 3-thienyl; R3 = H, alkyl] are prepared by cyclization of R2COCHRNHCOR1. Thus, NCCH2CO2Me was treated with 3-thiophenecarbonyl chloride to give 80% I (R = CO2Me, R1 = H, R2 = 3-thienyl), followed by ring cleavage with HCl to give 91% R2CONHMe.HCl and acylation with 4-FC6H4COCl to give 25.5% 4-FC6H4CONMeCOR2 (II). II was condensed with BrCH2CO2Et to give 66% R2COCH(CH2CO2Et)NHCOC6H4F-4 (R2 = 3-thienyl) which was cyclized with POCl3 to give 85.5% I (R = CH2CO2Et, R1 = 4-FC6H4, R2 = 3-thienyl) (III). At 50 mg-% in the diet III decreased serum cholesterol levels in rats by 19% and serum triglycerides by 31%. In rats, 100 mg IV/kg. orally, inhibited blood platelet aggregation 93 ± 6%.

IT 85162-13-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and esterification of)

RN 85162-13-6 CAPLUS

CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)- (CA INDEX NAME)



IT 85162-05-6P 85162-06-7P 85162-07-8P 85162-26-1P 85162-27-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)

RN 85162-05-6 CAPLUS

CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-06-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-07-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, methyl ester (CA INDEX NAME)



RN 85162-26-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-27-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chlorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



IT 85162-17-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and hypolipemic activity of)
RN 85162-17-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



IT 85162-04-5P 85162-09-0P 85162-11-4P
85162-12-5P 85162-14-7P 85162-20-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and hypolipemic and platelet aggregation-inhibition activity of)
RN 85162-04-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-09-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-11-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-12-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(2-thienyl)- (CA INDEX NAME)



RN 85162-14-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-20-5 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



IT 85162-08-9P 85162-10-3P 85162-15-8P
85162-16-9P 85162-18-1P 85162-19-2P
85162-21-6P 85162-22-7P 85162-23-8P
85162-24-9P 85162-25-0P 85162-28-3P
85162-29-4P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 85162-08-9 CAPLUS

CN 4-Oxazoleacetic acid, 2-phenyl-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-10-3 CAPLUS

CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 85162-15-8 CAPLUS

CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



RN 85162-16-9 CAPLUS

CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, potassium salt (9CI) (CA INDEX NAME)



RN 85162-18-1 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-19-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-phenyl-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-21-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-22-7 CAPLUS

CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-23-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, pentyl ester (CA INDEX NAME)



RN 85162-24-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-(3-thienyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 85162-25-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-chlorophenyl)-5-(3-thienyl)-, butyl ester (CA INDEX NAME)



RN 85162-28-3 CAPLUS
CN 4-Oxazoleacetic acid, 2-(2-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 85162-29-4 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chlorophenyl)-5-(3-thienyl)- (CA INDEX NAME)



L23 ANSWER 33 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:443087 CAPLUS Full-text
DOCUMENT NUMBER: 95:43087
ORIGINAL REFERENCE NO.: 95:7377a,7380a
TITLE: Oxazolinalkanoic acid, its salts and ester, and a pharmaceutical containing them
INVENTOR(S): Lautenschlaeger, Hans Heiner; Betzing, Hans; Stoll, Brigitte; Probst, Manfred
PATENT ASSIGNEE(S): Nattermann, A., und Cie G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 26 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 2935902	A1	19810402	DE 1979-2935902		19790905 <--
PRIORITY APPLN. INFO.:			DE 1979-2935902	A	19790905 <--

OTHER SOURCE(S): CASREACT 95:43087; MARPAT 95:43087
GI



I

AB The title compds. [I; R = H, aryl, C1-6 alkyl, alkali metal cation; R1, R2 = H, (substituted) Ph, thienyl; n = 1-11] were prepared for use as blood platelet aggregation inhibitors (test data tabulated). Thus, 4,5-diphenyl-4-oxazolin-2-one was treated with NaH in DMF, followed by the addition of Br(CH2)7CO2Me and NaI to give 59% I (R = Me, R1 = R2 = Ph, n = 7).

IT 78285-16-2P 78285-34-4P 78285-48-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 78285-16-2 CAPLUS
CN 3(2H)-Oxazoleacetic acid, 2-oxo-5-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 78285-34-4 CAPLUS
CN 3(2H)-Oxazoleacetic acid, 2-oxo-5-(2-thienyl)- (CA INDEX NAME)



RN 78285-48-0 CAPLUS
CN 3(2H)-Oxazoleacetic acid, 2-oxo-5-(2-thienyl)-, sodium salt (9CI) (CA INDEX NAME)



● Na

L23 ANSWER 34 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:443088 CAPLUS Full-text
DOCUMENT NUMBER: 95:43088
ORIGINAL REFERENCE NO.: 95:7377a,7380a
TITLE: Process for preparing thiazoles
INVENTOR(S): Bushell, Brian John
PATENT ASSIGNEE(S): John Wyeth and Brother Ltd., UK
SOURCE: Brit., 5 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
GB 1574583	A	19800910	GB 1978-5229		19780524 <--
PRIORITY APPLN. INFO.:			GB 1978-5229	A	19780524 <--

GI



I

AB Thiazoles I (R, R1 = aryl; R2 = C2-4 carboxyalkyl) were prepared by halogenating a ketone R1COCH2R2 (R1, R2 as before) to give the halo derivative R1COCHR2R3 (R3 = halo) which was maintained in solution and treated with a thio amide RCSNH2 (R as before). I and their salts with pharmaceutically acceptable bases are useful as antiinflammatory agents (no data). E.g., a solution of 1.55 kg p-ClC6H4CO(CH2)2CO2H (II) in 4.65 L CH2Cl2 and 15 mL HBr in HOAc was treated by addition during 1-1.5 h of 1.224 kg Br to give p-ClC6H4COCHBrCH2CO2H (>98%). The solvent was distilled off and replaced simultaneously by DMF and the mixture was treated by addition during 15 min of 1 kg PhCSNH2 at 50-60°, the temperature being maintained during 2 h. The product was precipitated by H2O and washed to give I (R = Ph, R1 = C6H4Cl-p, R2 = CH2CO2H) (90-1% on II).

IT 23821-65-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as inflammation inhibitor)

RN 23821-65-0 CAPLUS

CN 5-Thiazoleacetic acid, 2-(2-methylphenyl)-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 35 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:424289 CAPLUS Full-text
DOCUMENT NUMBER: 89:24289
ORIGINAL REFERENCE NO.: 89:3777a,3780a
TITLE: 5-Alkoxy-4-thiazolealkanoic acids and their esters
INVENTOR(S): Yamanaka, Tsutomu; Ikeda, Kuniki; Osuga, Kunio
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
JP 53007669	A	19780124	JP 1976-82375		19760709	<--
PRIORITY APPLN. INFO.:			JP 1976-82375	A	19760709	<--

GI



I

AB Twenty title compds. I [R = R3R4C6H3 (R3, R4 = H, halo, alkyl, F3C), 4-hydroxy-3,5-di-tert-butylphenyl, thienyl, halothienyl, pyridyl, halopyridyl; R1 = alkyl; R2 = H, alkyl, aralkyl; Z = alkylene] were prepared by conversion of RCONHCH(CO2R1)ZCO2R5 (R5 = alkyl, aralkyl) to RCSNHCH(CO2R1)ZCO2R5 (II), dehydrative cyclization of II, and hydrolysis or esterification if needed. I had antithrombotic, hypolipemic, and antiinflammatory activites (no data). Thus, 98 g P2S5 and 120 g Et N-p-chlorophenyl-L-aspartate in (CH2Cl)2 were refluxed 90 min, 80 g celite and 115 g P2O5 were added, and the whole was refluxed 4 h to give 73 g I (R = 4-ClC6H4, R1 = R2 = Et, Z = CH2).

IT 66614-12-8P 66614-17-3P 66614-19-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 66614-12-8 CAPLUS
CN 4-Thiazoleacetic acid, 5-ethoxy-2-(2-thienyl)- (CA INDEX NAME)



RN 66614-17-3 CAPLUS
CN 4-Thiazoleacetic acid, 5-ethoxy-2-(2-thienyl)-, phenylmethyl ester (CA INDEX NAME)



RN 66614-19-5 CAPLUS
CN 4-Thiazoleacetic acid, 2-(5-chloro-2-thienyl)-5-ethoxy- (CA INDEX NAME)



L23 ANSWER 36 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:62377 CAPLUS Full-text
DOCUMENT NUMBER: 88:62377
ORIGINAL REFERENCE NO.: 88:9859a,9862a
TITLE: 5-Alkoxy-4-oxazolealkanoic acid derivatives
INVENTOR(S): Yamanaka, Tsutomu; Kohayakawa, Akihiro; Konishi, Mitsuhiro; Ikeda, Kuniki
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52095661	A	19770811	JP 1976-11669	19760204 <--
PRIORITY APPLN. INFO.:			JP 1976-11669 A	19760204 <--

GI



I



II

AB Forty-nine title derivs. I (R = substituted Ph, naphthyl, halonaphthyl, pyridyl, halopyridyl, furyl, halofuryl, thienyl, halothienyl; R1 = alkyl; m, n = 1,2; Z = H, alkyl, PhCH2, pyridylmethyl, alkylene) were prepared (1) by treatment of RCONHCH(CO2R1)(CH2)mCO2R2 (R2 = alkyl, PhCH2, pyridylmethyl) with dehydrating agents followed by hydrolysis if needed or (2) by reaction of II

or their reactive derivs. with R2R3 (R3 = halo, tosyl, mesyl, OH) or with R3Z1R3 (Z1 = alkylene). I had anticholesteremic (with data) antiinflammatory, analgesic, and antithrombotic (no data) activities. Thus, 30 g 4-ClC6H4CONHCH(CO2Et)CH2CO2Et, 26 g P2O5, and 16 g kieselguhr in (CH2Cl)2 were refluxed 30 min to give 17.8 g I (R = 4-ClC6H4, R1 = Z = Et, m = n = 1), which (50 g) was stirred with 10.4 g KOH in aqueous MeOH to give 31 g I (R = 4-ClC6H4, R2 = Et, Z = H, m = n = 1).

IT 59399-60-9P 59399-82-5P 65463-77-6P
65463-79-8P 65493-53-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59399-60-9 CAPLUS
CN 4-Oxazoleacetic acid, 5-ethoxy-2-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 59399-82-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-ethoxy-2-(2-thienyl)- (CA INDEX NAME)



RN 65463-77-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-chloro-2-thienyl)-5-ethoxy-, ethyl ester (CA INDEX NAME)



RN 65463-79-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-chloro-2-thienyl)-5-ethoxy- (CA INDEX NAME)



RN 65493-53-0 CAPLUS
CN 4-Oxazoleacetic acid, 2-(5-chloro-2-thienyl)-5-ethoxy-, 3-pyridinylmethyl ester (CA INDEX NAME)



L23 ANSWER 37 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:50706 CAPLUS Full-text
DOCUMENT NUMBER: 88:50706
ORIGINAL REFERENCE NO.: 88:8001a,8004a
TITLE: Studies on heterocyclic cation systems. XI. Syntheses of 2-disubstituted-amino-4-arylthiazol-5-ylalkanoic acids
AUTHOR(S): Hirai, Kentaro; Sugimoto, Hirohiko
CORPORATE SOURCE: Shionogi Res. Lab., Shionogi and Co., Ltd., Osaka, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1977), 25(9), 2292-9
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 88:50706
GI



AB 2-Disubstituted-amino-4-arylthiazol-5-ylalkanoic acids I (R = piperidino, morpholino, MeNH, BzNH, p-ClC6H4CONH, R1 = H, Me; R2 = Ph, 2-thienyl, p-ClC6H4, p-BrC6H4) were prepared Thus, dehydration of S-(α-benzoyl- β-ethoxycarbonyl)ethyl 1-piperidinethiocarbonate in the presence of aqueous HClO4-Ac2O yielded 4-ethoxycarbonylmethyl-5-phenyl-2-piperidino-1,3-oxathiolium perchlorate, which underwent nucleophilic reaction with NH3 and the 5-ethoxycarbonylmethyl-4-phenyl-2-piperidinothiazole hydrolyzed to give I (R = piperidino, R1 = H, R2 = Ph). I were also synthesized by the classical

Hantzsch method. I were evaluated as antiinflammatory agents on carrageenin induced abscess in rats.

IT 65358-73-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 65358-73-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-(4-morpholinyl)-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



IT 61874-82-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 61874-82-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-(4-morpholinyl)-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 38 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1977:133781 CAPLUS Full-text

DOCUMENT NUMBER: 86:133781

ORIGINAL REFERENCE NO.: 86:20985a,20988a

TITLE: Agents improving lipid-metabolism in blood

INVENTOR(S): Yamanaka, Tsutomu; Kobayakawa, Toshihiro; Konishi, Mitsuhiro; Ikeda, Kuniki

PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 51110039	A	19760929	JP 1976-19801		19760224 <--
AU 7578694	A	19760902	AU 1975-78694		19750228 <--
PRIORITY APPLN. INFO.:			AU 1975-78694	A	19750228 <--
			JP 1974-29548	A	19740313 <--
			JP 1974-29549	A	19740313 <--
			JP 1974-29550	A	19740313 <--

GI



I

AB Alkoxyoxazolealkanoates were effective in controlling lipid metabolism of blood. The compds. may be used to treat thrombosis, arteriosclerosis, and hypertension. Thus, mice were fed a conventional mixed feed containing cholesterol 1, cholic acid 0.2, olive oil 5%, and Et 2-(p-chlorophenyl)-5-ethoxy-4-oxazoleacetate (I) [59399-41-6] 100 mg/kg/day for 5 days. Serum cholesterol of the treated mice was 45% less than that of controls.

IT 59399-82-5 59399-83-6
RL: BIOL (Biological study)
(anticholesteremic and hypolipemic)

RN 59399-82-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-ethoxy-2-(2-thienyl)- (CA INDEX NAME)



RN 59399-83-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chloro-2-thienyl)-5-ethoxy- (CA INDEX NAME)



L23 ANSWER 39 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:89798 CAPLUS Full-text
DOCUMENT NUMBER: 86:89798
ORIGINAL REFERENCE NO.: 86:14181a,14184a
TITLE: 2-Dialkylamino-4-aryl-5-thiazoleacetic acids
INVENTOR(S): Hirai, Kentaro; Sugimoto, Hirohiko
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 51088964	A	19760804	JP 1975-13159	19750130 <--
PRIORITY APPLN. INFO.:			JP 1975-13159 A	19750130 <--

GI


I


II

AB Thiazoleacetic acids I (R = optionally substituted phenyl, aromatic heterocycle; R1, R2 = alkyl or R1R2N = cyclic amino; R3 = H, alkyl; R4 = H, ester-forming group) were prepared by acid cyclization of R1R2NC(O)SCH(COR)CHR3CO2R5 III (R5 = ester-forming group) to II (X- = acid group) followed by treatment with NH3 and optional hydrolysis. I had antiinflammatory and analgesic activities in rats. Thus, III (R = p-ClC6H4, R1R2N = piperidino, R3 = H, R5 = Et), prepared from Na piperidine-1-carbothioate and Et 3-p-chlorobenzoyl-3-bromopropionate, was stirred with 70% HClO4 in Ac2O with ice cooling for 1 h to give 82% corresponding II (X = ClO4). The perchlorate was stirred with 28% NH4OH in CHCl3 at room temperature for 1 h to give 67% corresponding I (R4 = Et), which was hydrolyzed to I.HCl (R4 = H) in 39.9% yield by heating with concentrated HCl. Among 9 more I prepared were (R, R1R2N, R3, and R4 given): p-ClC6H4, morpholino, H, H (HCl salt); Ph, piperidino, Me, H; p-ClC6H4, morpholino, Me, H; p-ClC6H4, Et2N, H, Et.

IT 61874-82-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 61874-82-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-(4-morpholinyl)-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 40 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:421331 CAPLUS Full-text

DOCUMENT NUMBER: 85:21331
ORIGINAL REFERENCE NO.: 85:3489a,3492a
TITLE: 4-Oxazolealkanecarboxylic acid compounds
INVENTOR(S): Yamanaka, Tsutomu; Kobayakawa, Toshihiro; Konishi, Mitsuhiro; Ikeda, Kuniki
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2509634	A1	19750918	DE 1975-2509634	19750305 <--
JP 50123669	A	19750929	JP 1974-29548	19740313 <--
JP 50123678	A	19750929	JP 1974-29549	19740313 <--
JP 50123670	A	19750929	JP 1974-29550	19740313 <--
GB 1435293	A	19760512	GB 1975-8136	19750226 <--
FR 2263772	A1	19751010	FR 1975-6635	19750304 <--
BE 826375	A1	19750630	BE 1975-154077	19750306 <--
CH 597207	A5	19780331	CH 1975-2962	19750306 <--
SE 7502789	A	19750915	SE 1975-2789	19750312 <--
US 4012412	A	19770315	US 1975-557692	19750312 <--
SU 561511	A3	19770605	SU 1975-2115240	19750312 <--
NL 7502988	A	19750916	NL 1975-2988	19750313 <--
AT 345817	B	19781010	AT 1975-1920	19750313 <--
US 4053478	A	19771011	US 1976-748450	19761208 <--
AT 346844	B	19781127	AT 1977-7752	19771031 <--

PRIORITY APPLN. INFO.:

JP 1974-29548	A	19740313 <--
JP 1974-29549	A	19740313 <--
JP 1974-29550	A	19740313 <--
US 1975-557692	A3	19750312 <--
AT 1975-1920	A	19750313 <--

GI



I

AB Approx. 60 oxazolealkanoates I (R = 2-furyl, 2-thienyl, 2-naphthyl, p-tolyl, 3 pyridyl, etc.; R1 = Et, Bu; R2 = Et, 2-, 3-pyridyl, H, CH2Ph n = 1,2) were prepared Thus, 30 g N-(p-chlorobenzoyl)-L-asparagine di-Et ester was cyclized to give 17.8 g I (R = p-ClC6H4, R1 = R2 = Et, n = 1), which was hydrolyzed to give I (R = p-ClC6H4, R1 = Et, R2 = H, n = 1) (II). II was esterified to give I (R = p-ClC6H4, R1 = Et, R2 = Me, n = 1). Extensive data was given for the activity of I as anticholesteremics, antilipemics, and anticoagulants.

IT 59399-60-9P 59399-68-7P 59399-82-5P
59399-83-6P 59444-86-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59399-60-9 CAPLUS

CN 4-Oxazoleacetic acid, 5-ethoxy-2-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 59399-68-7 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chloro-2-thienyl)-5-ethoxy-, 3-pyridinylmethyl ester (CA INDEX NAME)



RN 59399-82-5 CAPLUS
CN 4-Oxazoleacetic acid, 5-ethoxy-2-(2-thienyl)- (CA INDEX NAME)



RN 59399-83-6 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chloro-2-thienyl)-5-ethoxy- (CA INDEX NAME)



RN 59444-86-9 CAPLUS
CN 4-Oxazoleacetic acid, 2-(3-chloro-2-thienyl)-5-ethoxy-, ethyl ester (CA INDEX NAME)



L23 ANSWER 41 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:38473 CAPLUS Full-text
DOCUMENT NUMBER: 82:38473
ORIGINAL REFERENCE NO.: 82:6066h,6067a
TITLE: Nonsteroidal antiinflammatory agents. 1. 2,4-Diphenylthiazole-5-acetic acid and related compounds
AUTHOR(S): Brown, Kevan; Cater, David P.; Cavalla, John F.; Green, David; Newberry, Robert A.; Wilson, Alan B.
CORPORATE SOURCE: Wyeth Inst. Med. Res., Taplow/Maidenhead/Berkshire, UK
SOURCE: Journal of Medicinal Chemistry (1974), 17(11), 1177-81
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Two title compds., 4-(4-chlorophenyl)-2-phenylthiazole-5-acetic acid (I) [18046-21-4] and 4-(4-chlorophenyl)-2-(3-methylphenyl)thiazole -5-acetic acid (II) [53514-97-9], had antiinflammatory activity comparable to that of indomethacin [53-86-1] on carrageenin induced rat paw edema. I was 5 times as effective as phenylbutazone [50-33-9] against adjuvant-induced polyarthritis in rats. The acidic side chain derivs. were less active than the parent compds. The compds. were prepared by the Hantzsch thiazole synthesis.
IT 23821-62-7P 23821-65-0P 23821-73-0P
23821-83-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiinflammatory activity of)
RN 23821-62-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-65-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(2-methylphenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-73-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-chlorophenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-83-2 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-methoxyphenyl)-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 42 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:53775 CAPLUS Full-text
DOCUMENT NUMBER: 74:53775
ORIGINAL REFERENCE NO.: 74:8673a,8676a
TITLE: Antiinflammatory 4-hydroxy-2-thiazoline -5-alkanoic acids
INVENTOR(S): Sulkowski, Theodore S.; Mascitti, Albert A.
PATENT ASSIGNEE(S): American Home Products Corp.
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 3539585	A	19701110	US 1968-764967		19681003 <--
PRIORITY APPLN. INFO.:			US 1968-764967	A	19681003 <--

GI For diagram(s), see printed CA Issue.
AB The title thiazolines I (R = Cl, CF3, or Br) are prepared by treating a heated mixture of p-RC6H4COCHBrCH2CO2H and Na2CO3 in Me2CHOH with PhCSNH2 and are readily converted into the corresponding thiazole derivs. by heating in toluene in the presence of MeC6H4SO3H.
IT 23821-62-7P 23821-65-0P 23821-73-0P
23821-83-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23821-62-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-65-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(2-methylphenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-73-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-chlorophenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-83-2 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-methoxyphenyl)-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 43 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:524422 CAPLUS Full-text
DOCUMENT NUMBER: 71:124422
ORIGINAL REFERENCE NO.: 71:23127a,23130a
TITLE: Antiinflammatory heterocyclic carboxylic acids
INVENTOR(S): Brown, Kevan; Cavalla, John F.
PATENT ASSIGNEE(S): John Wyeth and Brother Ltd.
SOURCE: S. African, 60 pp.

CODEN: SFXXAB
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
ZA 6706327		19690423	ZA		<--
PRIORITY APPLN. INFO.:			GB	19661118	<--
			GB	19670614	<--

GI For diagram(s), see printed CA Issue.

AB Antiinflammatory compds. (I-III) are prepared Thus, a mixture of 40 g. BzCHBrCH2CO2H and 21.3 g. thiobenzamide in 500 ml. EtOH was refluxed 8 hrs., concentrated, treated with 10 g. Na2CO3 in 300 ml. water and extracted with ether to give 35.2 g. I (R1 = R2 = Ph, X = CH2, R = Et) (IV), m. 95-6°. Hydrolysis of 15 g. IV in 150 ml. EtOH with 10 g. KOH in 20 ml. water 1 hr. gave 12.2 g. I (R1 = R2 = Ph, X = CH2, R = H), m. 152-3°. A solution of 1.9 g. I (R1 = R2 = Ph, X = CH2, R = Me) in 25 ml. MeOH was treated with NH4OH and heated in a sealed tube 5 hrs. at 90° to give 0.6 g. 2,4-diphenyl-5-thiazolylacetamide, m. 209-10°. A mixture of 21.2 g. benzoin and 10 g. succinic anhydride was heated 6 hrs. to 120°, dissolved in ether and extracted with dilute aqueous Na2CO3. The extract was washed with ether, acidified and extracted with ether to give 27 g. benzoin hemisuccinate (V), m. 88.5-9.5°. A mixture of 15 g. V and 30 g. NH4OAc in 100 ml. AcOH was refluxed for 1.5 hrs. and poured into water to precipitate II (R1 = R2 = Ph, X = CH2CH2, R = H), m. 160.5-1.5°; AcOCH2 ester, m. 86-6.5° (prepared in Me2NCHO in the presence of Et3N). PhCH2COCH2CO2Et (5.15 g.) was brominated with 4 g. Br in ether to give, after extraction with ether, 7.14 g. PhCHBrCOCH2CO2Et (VI). Reaction of 7.14 g. VI with 3.4 g. thiobenzamide gave 33.5% 2,5-diphenyl-4-thiazolylacetic acid, m. 171°, via its ester. A mixture of 68.8 g. α-bromodeoxybenzoin and 68.3 g. benzoyloxythioacetamide was converted to 58.5 g. 2-benzoyloxymethyl-4,5- diphenylthiazole (VII), m. 157-60°. Hydrolysis of VII with 10 g. KOH in EtOH for 30 min. gave 41.6 g. 2-hydroxymethyl-4,5-diphenylthiazole (VIII), m. 113-17°. Treatment of 12.9 g. VII with 20 ml. POCl3 gave 13.7 g. 2-chloromethyl-4,5-diphenylthiazole (IX), m. 76-8°. A warm solution of 12.9 g. IX in 100 ml. absolute EtOH was added to a refluxing solution of NaCH(CO2Et)2 [from 1.55 g. Na and 10.7 g. CH2(CO2Et)2] and refluxed 2 hrs. to give 18 g. di-Et 4,5-diphenyl-2- thiazolylmalonate which was hydrolyzed with 20 g. KOH in 20 ml. water to give 12.8 g. foamy material. The product in 25 ml. Me2NCHO was refluxed 1 hr. to give III (R1 = R2 = Ph, R = H, X = CH2CH2), m. 52-8°. Benzamide (3.02 g.) was added to a suspension of 1.2 g. NaH (50% in oil) in 200 ml. benzene, refluxed 0.5 hrs., treated with 7.14 g. VI in 30 ml. benzene 0.5 hrs., refluxed 1.5 hrs. and diluted with water. Work up gave 2,4-diphenyl-5-oxazolylacetic acid. Other derivs. are also similarly prepared A therapeutic capsule was prepared from 125 mg. I (R = H, X = CH2, R1 = Ph, R2 = p-ClC6H4), 120 mg. lactose. and 5 mg. Mg stearate.

IT 23821-62-7P 23821-65-0P 23821-73-0P
23821-83-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23821-62-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-65-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(2-methylphenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-73-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-chlorophenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-83-2 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-methoxyphenyl)-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 44 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:461375 CAPLUS Full-text
DOCUMENT NUMBER: 71:61375
ORIGINAL REFERENCE NO.: 71:11311a,11314a
TITLE: 2,4-Diarylthiazole-5-alkanoic acids
INVENTOR(S): Brown, Kevan
PATENT ASSIGNEE(S): John Wyeth and Brother Ltd.
SOURCE: Brit., 13 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1145884		19690319	GB 1966-51823	19661118 <--
DE 1670005			DE	
DE 1770177			DE	
FR 1584222			FR	
US 3476766		19691104	US	19671102 <--
US 3546342		19701208	US	19690521 <--

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) and their derivs., antiinflammatory and antibacterial, are prepared Thus, a mixture of 40 g. BzCHBrCH2CO2H (II) and 21.3 g. PhCSNH2 (III) in 500 ml. EtOH is refluxed 8 hrs. to give 70% I (R1 = R2 = Ph, R3 = CH2CO2Et) (Ia), m. 95-6° (EtOH). Similarly prepared are Ia analogs where R2 is p-MeOC6H4 (62%, m. 67.5-8.5°) and p-ClC6H4 (56%, m. 69-70°). A solution of 10 g. KOH in 20 ml. H2O is added to 15 g. Ia in 150 ml. warm EtOH and the mixture kept 1 hr. to give 89% I (R1 = R2 = Ph, R3 = CH2CO2H) (Ib), m. 152-3° (benzene). Similarly prepared are Ib analogs where R2 is p-MeOC6H4 (85%, m. 178.5-9.5°) and p-ClC6H4 (63%, m. 161-2°; Ic). A mixture of 13.6 g. BzCHBrCHMeCO2H and 6.9 g. III in 75 ml. iso-PrOH is heated 30 min. at 60°, 2.5 g. Na2CO3 added, and the mixture heated 10 min., and kept overnight to give 55% I (R1 = R2 = Ph, R3 = CHMeCO2H) (Id), m. 142-4° (HOAc-H2O). Similarly prepared are Ib analogs were R2 is 2-thienyl (48%, m. 134.5-5°) and p-tolyl [31%, m. 168-9° (benzene)]. A mixture of 4.2 g. 4-MeOC6-H4CSNH2 and 6.4 g. II in 50 ml. EtOH is refluxed 1.5 hrs. and kept overnight to give 43% I (R1 = 4-MeOC6H4, R2 = Ph, R3 = CH2CO2Et), m. 60.5-62° (industrial methylated spirit). A mixture of 5.7 g. 2-MeC6H4CSNH2 (IV), 10 g. 3-bromo-3-(2-thenoyl)propionic acid and 1.8 g. anhydrous Na2CO3 in 55 ml. iso-PrOH is stirred 30 min. at 60°, stirred for 1 hr. at 40°, cooled to room temperature, and kept overnight to give 46.2% I (R1 = o-tolyl, R2 = 2-thienyl, R3 = CH2CO2H), m. 136-8° (benzene). Similarly prepared are the following I (R3 = CH2CO2H) [R1, R2, % yield, m.p., and solvent (unless HOAc-H2O) given]: 4-ClC6H4, 4-MeOC6H4, 57.1, 199-201°; 4-ClC6H4, Ph, 44.2, 153-5°, benzene; 4-ClC6H4, 2-thienyl, 31.2, 137-9°, benzene; 4-MeOC6H4, 4-MeOC6H4, 56.3, 176-8°; 2-tolyl, 4-MeOC6H4, 44.6, 140-1°, benzene; 2-MeOC6H4, Ph, 78.3, 179-80.5°; 4,2-Cl(MeO)C6H3, Ph, 64.6, 204-5°; 2,6-ClMeC6H3, Ph, 63, 217-19°; 4,2-MeO-MeC6H3, Ph, 27.5, 136-8°; 4,2-ClMeC6H3, Ph, 58, 175-7°; 2-tolyl, 2-C10H7, -, 171-2°; 2,4-(MeO)2C6H3, Ph, 44.4, 157-9°; 4-Me2NC6H4, Ph, 12.4, 144-6°, benzene; 2,3-Me2C6H3, Ph, 64.2, 143-5°; 2,4-Cl2C6H3, Ph, -, 158-60°; 4-ClC6H4, 4-ClC6H4, 30.6, 194-6°. A mixture of 7.5 g. IV, 12.85 g. II, and 75 ml. iso-PrOH is stirred 30 min. at 60°, cooled to 40°, 2.5 g. anhydrous Na2CO3 added, a temperature of 40° held for 1 hr., and the mixture kept overnight to give 19.4% I (R1 = 2-tolyl, R2 = Ph, R3 = CH2CO2H), m. 165-7° [benzene-petroleum ether (b. 60-80°)]. Similarly prepared are the following I (R3 = CH2CO2H) [R1, R2, % yield, m.p., and solvent (unless benzene) given]: 4-MeO-C6H4, Ph, 40.6%, 149.5-52°; 2-ClC6H4, Ph, 27.6, 168-71°; 4-tolyl, Ph, 51.2, 170-1°; 1-C10H7, Ph, 29.7, 145-8°, benzenepetroleum ether; 3-F3CC6H4, Ph, 23.4, 143-5°, benzene-petroleum ether; 4-MeOC6H4, 2-thienyl, 13.3, 149-51°; 2-C10H7, Ph, 50.6, 171-2°; 4-MeOC6H4, 2-C10H7, 44.4, 160-2°, HOAc-H2O. A mixture of 26.5 g. BzCHBr(CH2)2CO2H (V), 16.7 g. 4-ClC6H4CSNH2, and 80 ml. EtOH is refluxed 3.5 hrs. to give 39 g. I (R1 = 4-ClC6H4, R2 = Ph, R3 = C2H4CO2H) (Ie) Et ester, and thence 37% Ie, m. 177-8° (benzene). Similarly prepared are I (R3, R1, R2, % yield, and m.p. given): CH2CO2H, Ph, 1-C10H7, 12, 166-7°; CH2CO2H, Ph, 2-C10H7, 31, 168-9°; C2H4CO2H, 4-MeC6H4, Ph, 21, 174-5°; CH2CH2CO2H, 2-tolyl, Ph, 18, 107-9°; CH2CH2CO2H, Ph, Ph, 50, 150° (EtOH). By refluxing 5 hrs. a mixture of 29.5 g. II, 15.7 g. III, and 300 ml. MeOH is obtained 70% I (R1 = R2 = Ph, R3 = CH2CO2Me) (If), m. 122-3°. A mixture of 1.9 g. If, 25 ml. MeOH, and 25 ml. NH3 solution (d. 0.88) is heated 5 hrs. at 90° in a sealed tube to give 33% I (R1 = R2 = Ph, R3 = CH2CONH2), m. 209-10° (benzene). To a solution of 2 g. Ic in 50 ml. dry tetrahydrofuran at 0° are added dropwise 0.68 g. Et3N and 0.73 g. ClCO2Et, while keeping the mixture at 0-5° (to give the mixed anhydride),

0.35 g. aqueous NH3 (d. 0.88) is added dropwise after 0.5 hr., and the mixture stirred 14 hrs. at room temperature to give 15% Ic amide, m. 223-4°. Thiobenzamides RR1C6H3CSNH2 (VI) required for the preceding prepns. are prepared, e.g., by passing H2S through a solution of 26.5 g. 4,2-Cl(MeO)C6H3CN in 22 ml. dry pyridine and 21 ml. Et3N until conversion is complete (.apprx.15 hrs.) to give 75.7% 4,2-Cl-(MeO)C6H3CSNH2, m. 149-50°. Other VI prepared similarly are (R,R1, % yield, and m.p. given): 2-Cl, 6-Me, 83, 126-9°; 4-MeO, 2-Me, 71, 124-6°; 2,4-(MeO)2, 68, -; 4-Me2N, H, 87.6, 218°; 2,3-Me2, 92, 137-8°; and 2,4-Cl2, -, -. Examples of a capsule and tablet containing Ie are given.

IT 23821-62-7P 23821-65-0P 23821-73-0P
23821-83-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23821-62-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-65-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(2-methylphenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-73-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-chlorophenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-83-2 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-methoxyphenyl)-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 45 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1970:43655 CAPLUS Full-text
DOCUMENT NUMBER: 72:43655
ORIGINAL REFERENCE NO.: 72:8023a,8026a
TITLE: 5-Thiazole-and 2-thiazoline -5-alkanoic acids
INVENTOR(S): Newberry, Robert A.
PATENT ASSIGNEE(S): John Wyeth and Brother Ltd.
SOURCE: Ger. Offen., 29 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1917432	A	19691106	DE 1969-1917432	19690403 <--
DE 1917432	C2	19831006		
GB 1262292	A	19720202	GB 1968-16909	19680409 <--
AT 306007	B	19730326	AT 1969-3150	19690331 <--
FI 54921	B	19781229	FI 1969-985	19690403 <--
FI 54921	C	19790410		
BE 731200	A	19691008	BE 1969-731200	19690408 <--
FR 2007419	A5	19700113	FR 1969-10756	19690408 <--
US 3607879	A	19710921	US 1969-814445	19690408 <--
PL 71273	B1	19740430	PL 1969-132832	19690408 <--
SE 390635	B	19770103	SE 1969-4950	19690408 <--
DK 138991	B	19781127	DK 1969-1929	19690408 <--
DK 138991	C	19790514		
NL 6905474	A	19691013	NL 1969-5474	19690409 <--
NL 165160	B	19801015		
NL 165160	C	19810316		
CH 513906	A	19711015	CH 1969-513906	19690409 <--
IN 140065	A1	19760904	IN 1975-CA89	19750115 <--
FI 7501343	A	19750507	FI 1975-1343	19750507 <--
FI 7601454	A	19760524	FI 1976-1454	19760524 <--
FI 57593	B	19800530		
FI 57593	C	19800910		

PRIORITY APPLN. INFO.:			
GB 1968-16909	A	19680409 <--
IN 1969-120606	A1	19690328 <--
FI 1969-985	A	19690403 <--

GI For diagram(s), see printed CA Issue.

AB The title products I and II, effective against inflammations, are prepared Thus, 3.43 g thiobenzamide, 8.4 g 3-(p-bromobenzoyl)-3-bromopropionic acid, and 1.33 g Na2CO3 in 50 ml iso-PrOH was stirred 0.5 hr at 60-70° to yield 3.14 g 4-(p-bromophenyl)-4-hydroxy-2-phenyl-2- thiazoline-5-acetic acid, m. 135-7°. Similarly was prepared I (R = Ph, R1 = p-chlorophenyl, R2 = CH2CO2 H), m. 148-50°, which was dehydrated in toluene with catalytic amts. p- toluenesulfonic acid to 4-(p-chlorophenyl)-2-phenyl-5-thiazoleacetic acid, m. 161-2°. By a similar procedure were prepared I [R = Ph, R1 = p-(trifluoromethyl)phenyl, R2 = CH2CO2H], m. 160-1°, addnl. appropriate I and the following II (R2 = CH2CO2H) (R, R1, and m.p. given): Ph, p-trifluoromethylphenyl, 168-9°; o-tolyl, 2-thienyl, 136-8°; p-chlorophenyl, p-methoxyphenyl, 199-201°; p-chlorophenyl, Ph, 153-5°; p-chlorophenyl, 2-thienyl, 137-9°; p-methoxyphenyl, p-methoxyphenyl, 176-8°; o-tolyl, p-methoxyphenyl, 140-1°; o-tolyl, Ph, 165-

7°; m-tolyl, Ph, 123-5°; p-methoxyphenyl, Ph, 149.5-52°; o-chlorophenyl, Ph, 168-71°; p-tolyl, Ph, 170-1°; 1-naph thyl, Ph, 145-8°; p-trifluoromethyl-phenyl, Ph, 143-5°; p-methoxyphenyl, 2-thienyl, 149-51°; 2-naphthyl, Ph, 171-2°; p-methoxyphenyl, 2-naphthyl, 160-2°; Ph, 1-naphthyl, 166-7°; Ph, 2-naphthyl, 168-9°; Ph, Ph, 152-3°; Ph, p-methoxyphenyl, 178.5-9.5°; Ph, 2-thienyl, 134.5-5.0°; Ph, p-tolyl, 168-9°; o-methoxyphenyl, Ph, 179-80°. Also prepared were the following II (R1 = Ph, R2 = CH2CH2CO2H) (R and m.p. given): p-ClC6H4, 177-8°; p-MeOC6H4, 174-5°; o-tolyl, 107-9°; Ph, 150°; and II (R = R1 = Ph, R2 = CHMeCO2H), m. 142-4°.

IT 23821-62-7P 23821-65-0P 23821-73-0P
23821-83-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23821-62-7 CAPLUS
CN 5-Thiazoleacetic acid, 2-phenyl-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-65-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(2-methylphenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-73-0 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-chlorophenyl)-4-(2-thienyl)- (CA INDEX NAME)



RN 23821-83-2 CAPLUS
CN 5-Thiazoleacetic acid, 2-(4-methoxyphenyl)-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 46 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1947:32760 CAPLUS
DOCUMENT NUMBER: 41:32760
ORIGINAL REFERENCE NO.: 41:6582i,6583a-d
TITLE: Azoles
INVENTOR(S): Knott, Edward B.
PATENT ASSIGNEE(S): Eastman Kodak Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2423709		19470708	US	<--

GI For diagram(s), see printed CA Issue.

AB Azoles of the formula (where R represents an aryl or 2-thienyl group, R' and R'' represent H, alkyl, or aryl, and R''' represents H, alkyl, mercapto, alkylmercapto, aralkylmercapto, or amino groups when X is S, and alkyl or amino groups when X is Se) are produced by the reaction of HXC(:NH)R''' with RCOCHBrCHR'CO2R''. Examples of compds. prepared, followed by their m.ps. are: 2-methyl-5-thiazoleacetic acids: 4-Ph 200-2°; 4-(4-ethylphenyl) 144°; 4-(4-isopropylphenyl), 173-4°; 4-(2,4-dimethylphenyl), 199-200°; 4-(4-methoxyphenyl), 189-90°; 4-(4-ethoxyphenyl), 188-90°; 4-(4-chlorophenyl) 200-4°; 4-(2-thienyl), 158-9°; 4-(1-naphthyl), 212-13°; 4-(2-naphthyl), 226-9°. 4-Phenyl-5-thiazoleacetic acids: 2-methylmercapto, 145°; 2-ethylmercapto, 116°. 2-Methylmercapto-5-thiazoleacetic acids: 4-(4-methylphenyl), 176°; 4-(1-naphthyl), 125°; 4-(2-naphthyl), 154°. 2-Amino-5-thiazoleacetic acids: 4-(2-thienyl), 202-3°; 4-(1-naphthyl), solid; 4-(2-naphthyl), 255-6°; 4-phenyl (Me ester), 230°. 5- Thiazolepropionic acids: 4-phenyl-2-methyl, 172-3°; 2-amino-4-phenyl. 2-Amino-4-phenylselenazole m. 253°. New γ-bromo-γ-acylpropionic acid intermediates prepared are: 4-methylbenzoyl, 122-4°; 4-ethylbenzoyl, oil; 4-isopropylbenzoyl, 73-5°; 2,4-dimethylbenzoyl, 98.5°; 3,4-dimethylbenzoyl, 99°; 4-ethoxybenzoyl, 130°; 4-chlorobenzoyl, 115-16°; 1-naphthoyl, 172-3°; 2-naphthoyl, 133-5°; 2-thenoyl, 127-8°; benzoyl (Me ester), b17 180°. γ-2-Thenoylpropionic acid m. 116.5-19.5°.

IT 300814-88-4P, 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)- 314032-13-8P, 5-Thiazoleacetic acid, 2-methyl-4-(2-thienyl)-
RL: PREP (Preparation)
(preparation of)

RN 300814-88-4 CAPLUS
CN 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)- (CA INDEX NAME)



RN 314032-13-8 CAPLUS
CN 5-Thiazoleacetic acid, 2-methyl-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 47 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1949:46496 CAPLUS Full-text
DOCUMENT NUMBER: 43:46496
ORIGINAL REFERENCE NO.: 43:8401d-h,8402a
TITLE: 4-Aryl-5-thiazoleacetic acids and esters
INVENTOR(S): Knott, Edward B.
PATENT ASSIGNEE(S): Kodak Ltd.
SOURCE: Addn. to C.A. 43, 5048d
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 593024		19471007	GB 1944-9516	19440518 <--

AB Addnl. compds. prepared were 4-phenyl-5-thiazoleacetic acid, m. 154-6°; the following derivs. of 2-methyl-5-thiazoleacetic acid: 4-phenyl (I), m. 202-3°, 4-p-tolyl, m. 200-2°, 4-(p-ethylphenyl), m. 155°, 4-(p-isopropylphenyl), m. 173-4°, 4-(2,4-xylyl), m. 199-200°, 4-(p-methoxyphenyl) (two forms, one m. 189-90°, the other m. 177-9°), 4-(p-ethoxyphenyl) (two forms, one m. 188-90°, the other m. 169-90°), 4-(p-chlorophenyl), m. 200-4°, 4-(2-thienyl), m. 158.9°, and 4-(2-naphthyl), m. 226-9°; α-(4-phenyl-2- methyl-5-thiazolyl)propionic acid, m. 172-3°; Me ester of I, m. 132-3°; the following derivs. of 2-amino-5- thiazoleacetic acid: 4-phenyl (II), m. 230-1°, 4-p-tolyl, m. 224° (decomposition), 4-(2-thienyl), m. 202-3°, 4-(1-naphthyl), no m.p. given, and 4-(2-naphthyl), m. 255-6°; α-(2-amino-4-phenyl-5-thiazolylpropionic acid, m. 240°; Me ester of II, m. 233°; 2-methylmercapto-4-phenyl-5- thiazoleacetic acid, m. 145°, monohydrate, m. 116°; 2-methylmercapto-4-p-tolyl-5-thiazoleacetic acid, m. 176°; 2-methylmercapto-4-(1-naphthyl)-5-thiazoleacetic acid, m. 125°; 2-methylmercapto-4-(2-naphthyl)-5- thiazoleacetic acid, m. 154°; and 2-amino-4-phenyl-5- selenazoleacetic acid, m. 253° with decomposition beginning at 196°. The following β-bromo-β-aroylpropionic acids used as starting materials for the above compds. were also prepared: β-(p-methylbenzoyl), m. 122-4°, β-(p-ethylbenzoyl) pale yellow oil, β-(p-isopropylbenzoyl), m. 73-5°, β-(2,4-dimethylbenzoyl), m. 98.5°, β-(3,4- dimethylbenzoyl), m. 99°, β-(p-ethoxybenzoyl), m. 130°, β-(p-chlorobenzoyl), m. 115-16°, β-1-naphthoyl, m. 172-3°, β-2-naphthoyl, m. 133-5°, and β-2-thenoyl, m. 127-8°. The preparation is given of β-1 (and 2)-naphthoylpropionic acid, β-2-thenoylpropionic acid, m. 116.5-19.5°, p-benzoylisobutyric acid, and β-bromo-β- benzoylisobutyric acid.

IT 300814-88-4P, 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)- 314032-13-8P, 5-Thiazoleacetic acid, 2-methyl-4-(2-thienyl)-
RL: PREP (Preparation)
(preparation of)

RN 300814-88-4 CAPLUS
CN 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)- (CA INDEX NAME)



RN 314032-13-8 CAPLUS
CN 5-Thiazoleacetic acid, 2-methyl-4-(2-thienyl)- (CA INDEX NAME)



L23 ANSWER 48 OF 48 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1945:29915 CAPLUS Full-text
DOCUMENT NUMBER: 39:29915
ORIGINAL REFERENCE NO.: 39:4869h-i,4870a-i,4871a-e
TITLE: Polycyclic thiazoles
AUTHOR(S): Knott, Edward B.
SOURCE: Journal of the Chemical Society (1945) 455-60
CODEN: JCSOA9; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 39:29915

AB A new method consists in first forming the thiazole ring by a normal Hantzsch condensation, followed by an intramol. cyclization to a condensed system, giving good yields of a variety of polycyclic thiazoles containing a HO group in the carbocyclic ring which is fused to the thiazole ring. β-Aroyl-β-bromopropionic acids were prepared from 250 g. of the ArCOCH2CH2CO2H in 2 l. hot CHCl3 by adding 5 cc. Br, heating until the Br was absorbed, and then adding the remainder of the Br (1 mol in all), which is readily absorbed without heating; 4-methylbenzoyl, m. 122-4°; 4-ethylbenzoyl, pale yellow oil; 4-isopropylbenzoyl, m. 73-5°; 2,4,dimethylbenzoyl, m. 98.5°; 4-chlorobenzoyl, m. 115-16°; 4-ethoxybenzoyl, m. 130°; 1-naphthoyl, m. 172-3°; 2-isomer, m. 133-5°: 2-thenoyl, m. 127-8°. β-Bromo-β-benzoylisobutyric acid, m. 163°. The acid (1 mol), 1 mol of CS(NH2)2, and 500 cc. iso-PrOH were boiled 15 min., 0.5 mol anhydrous Na2CO3 added, and the heating continued until evolution of CO2 ceased; the base was precipitated with H2O and crystallized from EtOH or aqueous EtOH; the yield was 90-8%. The following 2-amino-5- thiazoleacetic acids were prepared in this manner: 4-Ph, m. 230-1° (Me ester, pale yellow, m. 167-8°); 4-(4-methylphenyl), m. 224°; 4-(1-naphthyl), yellow, m. 258-9°; 4-(2-naphthyl), m. 255-6°; 4-(2-thienyl), m. 202-3°. α-(2-Amino-4-phenyl-5-thiazolyl)propionic acid, m. 240°, 83% yield. The Br acid (1 mol), 1 mol MeCSNH2, and 500 cc. iso-PrOH were heated to 50° (temperature kept below 65° by cooling) and after 1-2 h. (temperature of 40°) 0.5 mol of anhydrous Na2CO3 added and the mixture allowed to stand 1-2 days, giving the following 2-methyl-5-thiazoleacetic acids: 4-Ph, m. 202-3°, 93.5%; 4-(4-methylphenyl), m. 200-2°, 90%; 4-(4-ethylphenyl), cream, m. 155°, 60%; 4-(4-isopropylphenyl),

cream, m. 173-4°, 74%; 4-(2,4-dimethylphenyl), m. 189-90°, 86%; 4-(4-chlorophenyl), m. 200-4°, 91%; 4-(1-naphthyl), m. 212-13°, 43%; 4-(2-naphthyl), m. 226-9°, 68%; 4-(2-thienyl), prepared without heating, m. 158-9°; 4-(4-methoxyphenyl), m. 189-90° (45% as the 1st crop), shows weak white fluorescence in UV light, and m. 171-9° (43% as the 2nd crop), shows blue-green fluorescence, reverts to the higher-melting form on recrystn.; 4-(4-ethoxyphenyl), m. 188-90° (12%), m. 169-90° (73% as 2nd crop), shows bright green fluorescence, reverting to the 1st form on recrystn. α-(4-Phenyl-2-methyl-5-thiazolyl)propionic acid, m. 172-3°, 10% yield. Condensation of 1 mol of the Br acid and 1 mol of an alkyl dithiocarbamate by shaking at room temperature in 1 l. iso-PrOH until solution results and allowing to stand 48 h. gives 5- thiazoleacetic acids as follows: 2-methylmercapto-4-Ph, m. 145°, 39%; 2-ethylmercapto-4-Ph, m. 116°, 23%; 2-methylmercapto-4-(4-methylphenyl), m. 176°, 38%; 2-methylmercapto-4-(2-naphthyl), m. 154°, 42%; the 1-naphthyl isomer, m. 125°, was prepared by heating the reactants to 60°, adding 0.5 mol of anhydrous Na_2CO_3, and allowing the mixture to stand 48 h. The thiazoleacetic acids (10 g.), 2.5 g. anhydrous AcONa, and 40 cc. Ac_2O were refluxed; the 4-Ph derivs. required 3 h., the 4-$C_{10}H_7$ analogs 5-30 min. depending on the substituent, the 4-thienyl analog 30 min.; the reaction mixture was diluted with 10 cc. AcOH and poured into 250 cc. H_2O; the yields varied 30 to 90%; the acetates were hydrolyzed with excess cold aqueous 2 N NaOH in hot or cold EtOH. The ethers were prepared from the phenols and alkyl sulfates in alkali at 60°. Naphtha-1',2',4,5-thiazoles: 2-acetamido-4'-acetoxy, pale yellow, m. 286°; 2-acetamido-4'-acetoxy-6'-Me, cream, m. 286°; 4'-hydroxy-2-Me, yellow, m. 252° (sublimes) (acetate, cream, m. 140-1°); 4'-methoxy-2-Me, yellow, m. 100°; 4'-ethoxy-2-Me, yellow, m. 147-8°; 4'-benzoyloxy-2-Me, m. 169°; 4'-hydroxy-2,6'-dimethyl, pale yellow, m. 250° (decomposition) (acetate, m. 162°); Me ether, greenish, m. 103-4°; Et ether, pale yellow, (m. 121-2°); 4'-benzoyloxy-2,6'-dimethyl, m. 162-3°; 4-hydroxy-2-methyl-6'-Et, m. 248° (decomposition) (acetate, m. 122.5°); Me ether, m. 65°; Et ether, yellow, (m. 87-8°); 4'-hydroxy-2-methyl-6'- iso-Pr, yellow, m. 231° (acetate, m. 101-1.5°; Me ether, pale yellow, m. 63-4°; Et ether, yellow, m. 91°); 4'-hydroxy-2,6',8'-trimethyl, yellow, m. 198° (acetate, m. 181°; Me ether, m. 91-2°; Et ether, pale yellow, m. 131°); 4'-hydroxy-6'-methoxy-2-Me, m. 257° (decomposition) (acetate, m. 161-2°; Me ether, m. 74°; Et ether, pale yellow, m. 115-16°); 4'-hydroxy-6'-ethoxy-2-Me, cream, m. 243° (decomposition) (acetate, yellow, m. 160-2°; Me ether, pale yellow, m. 120-1°; Et ether, yellow, m. 145-6°); 6'-chloro-4'-hydroxy-2-Me, m. 280° (decomposition) (acetate, m. 209-10°; Me ether, pale yellow, m. 134.5°; Et ether, yellow, m. 183.5°); 4'-hydroxy-2-methylmercapto, pale yellow, m. 255° (acetate, pale yellow, m. 143°; Me ether, m. 110-11°); 4'-hydroxy-2-ethylmercapto, m. 206° (acetate, m. 101-3°); 4'-hydroxy-2-methylmercapto-6'-Me, yellow, m. 213° (sublimes) (acetate, yellow, m. 155-6°; Me ether, m. 109-10°); 4'-hydroxy-2,3'-dimethyl, m. 300° (acetate, m. 171-2°; Me ether, pale yellow, m. 91-2°; Et ether, pale yellow, m. 100-1°); 2-acetamido-6'-acetoxy-3'-Me, m. 300°. Phenanthra-4',3',4,5-thiazoles: 2-acetamido-1'-acetoxy, m. 279° 1'-hydroxy-2-Me, pale yellow, m. 260° (sublimes) (acetate, m. 167-9°; Me ether, pale yellow, m. 136-7°; Et ether, pale yellow, m. 144-5°); 1'-hydroxy-2-methylmercapto, yellow, m. 162-4° (acetate, pale yellow, m. 128-9°). Phenanthra-1',2',4,5-thiazoles: 2-acetamido-4'-acetoxy, m. 290°; 4'-hydroxy-2-Me, yellow, m. 278-80° (sublimes) (acetate, m. 159.5°; Me ether, yellow, m. 173°; Et ether, yellow, m. 177.5°); 4'-hydroxy-2-methylmercapto, yellow, m. 240° (sublimes) (acetate, m. 152°). Thianaphtheno[7',6',4,5]thiazoles: 2-acetamido-4'-acetoxy, cream, m. 285-9°; 4'-hydroxy-2-Me, m. 268° (sublimes) (acetate, pink, m. 130-30.5°; Me ether, m. 127.5-8°). A byproduct from the cyclization of 4-phenyl-2-methyl-5- thiazoleacetic acid is about 20% of 4'-acetoxy-3'-acetyl-2- methylnaphtha-1',2',4,5-thiazole, m. 205°; hydrolysis with 2 N NaOH in hot EtOH gives 4'-hydroxy-3'-acetyl-2-methylnaphtha-1',2',4,5-thiazole, yellow, m. 126-7°; 2,4-dinitrophenylhydrazone, scarlet, m. 300°; hydrazone, orange, m. 173°; Me ether, pale yellow, m. 113-14°; this was

prepared also from 4'-hydroxy-2-methyl-β-naphthathiazone, AcCl or Ac2O, and AlCl3 in PhNO2. 4'-Hydroxy-3'-acetyl-2,6'-dimethylnaphtha-1',2',4,5-thiazole, yellow, m. 165-6°; acetate, cream, m. 216° (2,4-dinitrophenylhydrazone, orange, m. 306°). 4'-Hydroxy-3'-chloroacetyl-2,6'-dimethylnaphtha-1',2',4,5-thiazole could not be crystallized and was analyzed as the acetate, m. 170-1°; with hot 2 N Na2CO3 it yields 3'-keto-2-methylbenzocoumarano-5',4',4,5- thiazole, pale yellow, m. 233°; with 2-methylmercaptoquinoline-MeI in EtOH containing 2 drops of Et3N (boiling 15 min.) this yields 2-(1-methyl-1,2-dihydroquinolylidene)-2'-(3'-keto-2-methylbenzocoumarano-5',4',4,5-thiazole), red, m. 300°; the dye sensitizes a AgCl photog. emulsion at 4850 and 5200 A.

IT 300814-88-4P, 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)- 314032-13-8P, 5-Thiazoleacetic acid, 2-methyl-4-(2-thienyl)-
RL: PREP (Preparation)
(preparation of)

RN 300814-88-4 CAPLUS
CN 5-Thiazoleacetic acid, 2-amino-4-(2-thienyl)- (CA INDEX NAME)



RN 314032-13-8 CAPLUS
CN 5-Thiazoleacetic acid, 2-methyl-4-(2-thienyl)- (CA INDEX NAME)



=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	297.20	516.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-38.40	-38.40

STN INTERNATIONAL LOGOFF AT 16:58:12 ON 11 APR 2008